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Stroke is the second leading cause of death in the world behind coronary heart 
disease. There are 15 million cases worldwide each year, which cause 5 million 
deaths and another 5 million patients left with permanent disabilities. The long-term 
caring of stroke patients poses great economic burden worldwide. Ischemic stroke 
accounts for about 80% of stroke. Current treatment of ischemic stroke mainly relies 
on thrombolysis. However, thrombolytic drugs had to be applied very soon after 
ischemia, and it gave rise to a risk of hemorrhage. Alternatively, neuroprotective 
drugs would be useful in protecting brain cells after ischemia. 
Chinese herbs Danshen (Salviae Miltiorrhizae Radix et Rhizoma) and Gegen 
(Puerariae Lobatae Radix) were traditionally used for treating cardiovascular 
diseases. The Danshen-Gegen 7:3 (w/w) (DG) water extract was previously shown to 
have cardiovascular tonic effects such as vasodilation, anti-oxidation and inhibition 
of foam cell formation. Due to the vascular tonic effects of DG extract, its effect on 
cerebral ischemia was evaluated in the present study. 
Middle cerebral artery occlusion (MCAO) using intraluminal filament was 
employed as an in vivo transient ischemic model in rats mimicking the 
ischemia-reperfusion (IR) in stroke patients. It was a common and simple model 
which allowed minimal invasiveness and easy reperfusion by retracting the filament 
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from the vessel. The results indicated that pretreatment with DG extract at 3 g/Kg per 
OS (10 times human equivalent dose) for 7 days significantly lowered the percentage 
of brain infarction as well as the neurological deficit after cerebral IR. A 
dose-dependent protection on brain infarction and neurological deficit was observed. 
Moreover, pretreatments with DG extract at 0.3 g/Kg and 3 g/Kg were found to 
be able to elevate the activities of anti-oxidative enzymes, including superoxide 
dismutase (SOD), catalase and glutathione peroxidase (GPX), after cerebral IR, with 
the increased activities of both catalase and GPX being dose-dependent, suggesting 
that the protective mechanism of DG extract was partly mediated by the 
anti-oxidative mechanism. 
A shuttle box avoidance test was employed to evaluate the effect of DG extract 
on memory retention after cerebral IR. Both pretreatment and pre- and post treatment 
of DG extract did not show significant improvement on memory retention using this 
avoidance test. 
Besides, the effect of pretreatment with DG extract on anti-blood coagulation 
was tested. In rats pretreated with DG extract for 5 days, dose-dependent increases in 
tail bleeding time, number of rebleedings, volume of blood loss in tail bleeding, 
prothrombin time as well as anti-platelet aggregation activity were observed, and the 




In conclusion, our study demonstrated for the first time that the extract of DG 
(7:3, w/w) could produce a protective effect against cerebral IR presumably by 
virtues of anti-oxidative and anti-blood coagulation properties. However, no effect on 








































I would like to thank God, our Father in Heaven, who led me through the many 
troughs throughout the course of this project. It was an opportunity for me to build 
up my faith in Him and have a glance at His great creations through the precise 
biological systems. 
I would like to thank Prof. K. P. Fung, who gave me the chance to work on this 
project and have a taste on scientific researching, as well as kindly encourages me 
through the study period. Moreover, my sincere gratitude goes to Prof. Clara Lau, for 
her patience and valuable advices on planning of the experiments and through the 
processes of research and thesis writing. 
I am greatly indebted to Dr. Johnny Koon for his patient guidance on various 
aspects of my study, which benefited me not only on the study but also on my 
personal development. I must also thank him for his help in the anti-blood 
coagulation assays. Besides, special thanks are given to Prof. Joan Zuo of the School 
of Pharmacy for providing the data on the HPLC profile of the DG extracts, and Dr. 
H. Cao of the National Engineering Research Centre for Modernization of TCM, 
Zhuhai, China, for morphological authentication of the herbs. 
I am grateful to have the help of Ms. Y. L. Wong and Ms. Carmen Xian on the 
MCAO surgery and shuttle box training. I would also like to thank Mr. Eric Wong for 
viii 
Acknowledgements 
his help on the TLC analyses of the herbs and extracts. 
I would like to acknowledge the technical assistance of Ms. Virginia Lau, Ms. 
Julia Lee and Mr. C. P. Lau. Besides, I would like to thank Ms. S. W. Cheng and Ms. 
L. Li for their support, both technically and emotionally, which encouraged me in the 
darkest moments of my study. 
Furthermore, my heartfelt thanks go to my colleagues, Mr. Chellen Liu and Mr. 
C. F. Ng, who have always supported me throughout the years of study and shared 
my joy and bitterness in the process. I also thank the friendship and encouragement 
of all students and staff of the Institute of Chinese Medicine. 
Last but not least, I would like to thank my parents for their unconditional 
support in these years, which finally let me finish this M. Phil, project. 
The work described in the thesis was supported by a grant from the University 
Grants Committee of the Hong Kong Special Administrative Region, China under 
the Area of Excellence project ‘Chinese Medicine Research and Further 
Development' (Project No. AOE/B-10/01). 
ix 
Table of contents 
Table of contents 
Thesis / Assessment Committee ii 
Abstract (English) iii 
Abstract (Chinese) vi 
Acknowledgements viii 
Table of contents x 
List of figures xvi 
List of tables xix 
Abbreviations xx 
Chapter 1 Introduction 1 
1.1 Cerebral stroke 1 
1.2 Epidemiology 2 
1.3 Risk factors and symptoms 5 
1.3.1 Non-modifiable risks 5 
1.3.2 Modifiable risks 6 
1.3.3 Symptoms 9 
1.4 Mechanisms of cell injury 10 
1.4.1 Energy failure and loss of ionic homeostasis 10 
XV 
Table of contents 
1.4.2 Excitotoxicity and calcium-modulated cell damage 11 
1.4.3 Oxidative stress 13 
1.4.4 Inflammation 16 
1.4.5 Apoptosis 18 
1.5 Current treatment of ischemia 19 
1.6 Chinese herbal medicine 21 
1.6.1 Traditional Chinese medicine theory on stroke 21 
1.6.2 Danshen 22 
1.6.3 Gegen 25 
1.6.4 Danshen-Gegen formula 28 
1.7 Aim of study 30 
Chapter 2 General methodology 31 
2.1 Induction of transient focal cerebral ischemia by middle cerebral artery 
occlusion (MCAO) 31 
2.1.1 Intraluminal filament production 32 
2.1.2 Cerebral blood flow measurement by laser Doppler flowmetry……33 
2.1.3 Middle cerebral artery occlusion 35 
2.2 Neurological scoring 38 
2.3 Brain infarction measurement by triphenyltetrazolium chloride (TTC) 
xi 
Table of contents 
Staining 40 
2.4 Statistical analyses 42 
Chapter 3 Preparation of herbal medicine 43 
3.1 Authentication of Chinese herbs 43 
3.1.1 Morphological authentication 43 
3.1.2 Chemical authentication using thin layer chromatography 44 
3.1.2.1 Danshen 44 
3.1.2.2 Gegen 48 
3.2 Danshen-Gegen (DG) extract preparation 50 
3.3 Chemical analysis of DG extract 51 
3.3.1 TLC 51 
3.3.2 HPLC 54 
3.4 Conclusion 57 
Chapter 4 Protective effect of DG extract on cerebral ischemia 58 
4.1 Introduction 58 
4.1.1 Different models of ischemia 58 
4.11 Anti-oxidative enzymes in cerebral ischemia 61 
4.1.2.1 Superoxide dismutase (SOD) 61 
4.1.2.2 Catalase 62 
xii 
Table of contents 
4.1.2.3 Glutathione peroxidase (GPX) 62 
4.2 Materials and methods 64 
4.2.1 DG extract treatment, neurological deficit and brain infarction 64 
4.2.2 Anti-oxidative enzymes activity determination 65 
4.2.2.1 Treatment with DG extract and induction of cerebral 
ischemia 65 
4.2.2.2 Extraction of enzymes from the brain 66 
4.2.2.3 Determination of protein concentration 66 
4.2.2.4 Assay kits 67 
4.3 Results 70 
4.4 Discussion 80 
4.4.1 Neurological score and percentage brain infarction 80 
4.4.2 Anti-oxidative enzyme induction 82 
Chapter 5 Behavioral assessment using the shuttle box avoidance test on rats 
suffering from cerebral ischemia: effect of DG extract 
treatment 86 
5.1 Introduction 86 
5.1.1 Behavioral tests 86 
5.1.2 Theory of the test 90 
xiii 
Table of contents 
5.2 Materials and methods 91 
5.2.1 DG extract treatment 91 
5.2.2 Shuttle box training and MCAO 92 
5.2.3 Shuttle box testing 96 
5.2.4 Neurological score and brain infarction 96 
5.3 Results 97 
5.3.1 Shuttle box performance 97 
5.3.2 Neurological score 105 
5.3.3 Brain infarction 109 
5.4 Discussion 112 
5.4.1 The shuttle box protocol 112 
5.4.2 Shuttle box performance 114 
5.4.2.1 Pretreatment groups 114 
5.4.2.2 Pre + post treatment groups 115 
5.4.2.3 Comparison of pretreatment and pre + post treatment 
groups 116 
5.4.3 Neurological score 117 
5.4.4 Brain infarction 118 
5.4.5 Conclusion 119 
xiv 
Table of contents 
Chapter 6 Anti-blood coagulation effect of DG extract 121 
6.1 Introduction 121 
6.2 Materials and methods 125 
6.2.1 Treatment with DG extract and warfarin 125 
6.2.2 Tail bleeding time and volume 126 
6.2.3 Prothrombin time 127 
6.2.4 Platelet aggregation 127 
6.3 Results 128 
6.4 Discussion 138 
Chapter 7 General discussion 141 
7.1 General discussion and conclusion 141 
7.2 Clinical significance of the study 145 
7.3 Limitations of the study 146 




List of figures 
List of figures 
Figure 2.1 The silicone coated intraluminal filament head 33 
Figure 2.2 Location of the laser Doppler probe holder on the right hemisphere....34 
Figure 2.3 Location of the laser Doppler probe holder on the skull of the rat 34 
Figure 2.4 The procedure of MCAO 35 
Figure 2.5 The trifurcation of the CCA, ICA and ECA at the thoracic region...36 
Figure 2.6 Neurological scores given to rats after MCAO 39 
Figure 2.7 The brain matrix used to slice the brain 41 
Figure 2.8 Representative photo of brain slice 41 
Figure 3.1 The raw herbs of Danshen and Gegen used in the study 43 
Figure 3.2 Details of the TLC profile of Danshen using developing system 1 45 
Figure 3.3 Details of the TLC profile of Danshen using developing system 2 ……47 
Figure 3.4 Details of the TLC profile of Gegen 49 
Figure 3.5 Dried powder of DG extract 51 
Figure 3.6 TLC chromatogram of DG extract 53 
Figure 3.7 Representative HPLC profile of the DG extract used in the study ……56 
Figure 4.1 Principle of the SOD assay kit 68 
Figure 4.2 Neurological score of different groups of rats after 7 days DG extract 
pretreatment 
XV i 
List of figures 
Figure 4.3 Percentage of brain infarction of different groups of rats after 7 days 
DG extract pretreatment 73 
Figure 4.4 Specific SOD activity of the brain of different groups of rats at 24 hours 
of reperfusion 75 
Figure 4.5 Specific catalase activity of the brain of different groups of rats at 24 
hours of reperfusion 77 
Figure 4.6 Specific GPX activity of the brain of different groups of rats at 24 hours 
of reperfusion 79 
Figure 5.1 The radial arm maze 87 
Figure 5.2 Diagram of the water maze test 88 
Figure 5.3 The shuttle box used in our study for behavioral assessment 90 
Figure 5.4 Schematic diagram of the shuttle box experiment 92 
Figure 5.5 Schematic diagram of each shuttle box trial 93 
Figure 5.6 Shuttle box experiment in a classical active avoidance paradigm 95 
Figure 5.7 Percentage of conditioned response in the 2-way shuttle box for the 
pretreatment groups 98 
Figure 5.8 Percentage of conditioned response in the 2-way shuttle box for the pre 
+ post treatment groups 100 
Figure 5.9 Performance of the rats in the testing series as compared to the last day 
xvii 
List of figures 
of training for the pretreatment groups 102 
Figure 5.10 Performance of the rats in the testing series as compared to the last 
day of training for the pre + post treatment groups 104 
Figure 5.11 Neurological score of shuttle box rats of pretreatment groups after 
MCAO 106 
Figure 5.12 Neurological score of shuttle box rats of pre + post treatment groups 
after MCAO 108 
Figure 5.13 Percentage brain infarct of pretreatment groups of rats of shuttle box 
test at last day of testing 110 
Figure 5.14 Percentage brain infarct of pre + post treatment groups of rats of 
shuttle box test at last day of testing I l l 
Figure 5.15 The brain slice showing the different areas damaged by MCAO....114 
Figure 6.1 The blood coagulation cascade 122 
Figure 6.2 Tail bleeding time of different groups of rats 129 
Figure 6.3 Number of rebleedings in different groups of rats 131 
Figure 6.4 Blood loss of different groups of rats during the tail bleeding test•....133 
Figure 6.5 Prothrombin time of the plasma of different groups of rats 135 
Figure 6.6 Percentage inhibition of platelet aggregation in different groups of 
rats 137 
xviii 
List of tables 
List of tables 
Table 2.1 Neurological scores given to rats after MCAO 38 
Table 2.2 Configuration of the scanning software used for capturing images of the 
brain slices 42 
Table 3.1 Voucher specimen numbers of Danshen and Gegen 50 




AAPH 2,2'-azo-bis-(2-amidinoproapne) dihydrochloride 
ACA Anterior cerebral artery 
ADP Adenosine diphosphate 
AMPA a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid\ 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BSA Bovine serum albumin 
CCA Common carotid artery 
DALY Disability-adjusted life year 
DG Danshen-Gegen 7:3 (w/w) compound formula 
EAAT Excitatory amino acid transporter 
EGA External carotid artery 
GP Glycoprotein 
GPX Glutathione peroxidase 
GSH Glutathione 
GR Glutathione reductase 
HDL High-density lipoprotein 
HED Human equivalent dose 
HPLC High performance liquid chromatography 
HRP Horseradish peroxidase 
ICAM Inter-cellular adhesion molecule 
ICA Internal carotid artery 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
INR International normalized ratio 
IR Ischemia-reperfusion 
KA Kainic acid 
LDL Low-density lipoprotein 
MCA Middle cerebral artery 
MCAO Middle cerebral artery occlusion 
N F - K B Nuclear factor kappa-light-chain-enhancer of activated B cells 
NMDA N-methyl-D-aspartic acid 
nNOS Neuronal nitric oxide synthase 
NO Nitric oxide 
NOS Nitric oxide synthase 
One-way ANOVA One-way analysis of variance 
XX 
Abbreviations 
OGD Oxygen-glucose deprivation 
PARP Poly(ADP-ribose) polymerase 
PBS Phosphate-buffered saline 
PCA Posterior cerebral artery 
PDA Photodiode array 
PRP Platelet-rich plasma 
ROS Reactive oxygen species 
SD Sprague-Dawley 
SEM Standard error of the mean 
SHR Spontaneously hypertensive rat 
SMC Smooth muscle cell 
SOD Superoxide dismutase 
TIA Transient ischemic attack 
TLC Thin layer chromatography 
TNF Tumor necrosis factor 
tPA Tissue plasminogen activator 
TTC Triphenyltetrazolium chloride 
USFDA United States Food and Drug Administration 
VCAM Vascular cell adhesion molecule 
vWF von Willebrand factor 
WHO World Health Organization 
WST-1 Water soluble tetrazolium salt 
XO Xanthine oxidase 
xxi 
Chapter 1 Introduction 
Chapter 1 Introduction 
1.1 Cerebral stroke 
Cerebral stroke is a prevalent type of cerebrovascular disease. The definition of 
stroke by the World Health Organization (WHO) is ‘rapidly developing clinical signs 
of focal or global disturbance of cerebral function, with symptoms lasting 24 hours 
or longer or leading to death, with no apparent cause other than of vascular origin' 
(WHO MONICA Project Principal Investigators, 1988). Some common symptoms of 
stroke include sudden loss of speech, sight or consciousness, numbness or weakness, 
especially on only one side of the face or body (Goldstein & Simel, 2005; McArthur 
et aL, 2011). If the symptoms are recovered within 24 hours, it is termed a transient 
ischemic attack (TIA) (Albers et al., 2002). 
Stroke occurs when the blood supply to the brain is interrupted. It could be 
broadly divided into hemorrhagic stroke or ischemic stroke. Hemorrhagic stroke 
occurs when an artery supplying the brain is burst, while ischemic stroke occurs 
when an artery supplying the brain is occluded (Edvinsson & Povlsen, 2011). In both 
cases, brain cells cannot receive enough supply of oxygen and glucose, hence they 
will soon become lack of energy and die rapidly. 
Hemorrhagic stroke is divided into two subtypes depending on the location of 
occurrence. Intracerebral hemorrhage or parenchymal hemorrhage occurs when 
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blood is leaked into the brain tissues and accounts for about 15% of total stroke cases. 
Subarachnoid hemorrhage occurs when blood is leaked into the space between the 
arachnoid mater and the pia mater (the subarachnoid space) and accounts for about 
5% of total stroke cases (Binder et al., 2009; Edvinsson & Povlsen, 2011). 
Ischemic stroke, the major type of stroke, accounts for about 80% of the total 
number of cases (Binder et al., 2009). There are also two subtypes of cerebral 
ischemia, thrombotic and embolic. For thrombotic ischemia, the clot occluding the 
artery is formed locally by atherosclerosis. For embolic ischemia, the clot is formed 
in other vessels, and being transported to the incident site in the bloodstream. During 
these conditions, the specific part of the brain supplied by the occluded artery is 
affected, which is termed focal ischemia. In particular, the middle cerebral artery 
(MCA) is the most commonly occluded vessel in ischemic stroke patients 
(O'Sullivan & Schmitz, 2007). Cerebral ischemia may also occur during cardiac 
arrest, in which blood supply of the whole brain is affected, which is called global 
ischemia. 
1.2 Epidemiology 
Stroke is a major health burden across the world. According to the WHO, stroke 
accounts for about 9.7% of the world's total death in 2004 and is the second leading 
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cause of death worldwide behind coronary heart disease (WHO, 2008). There are 15 
million cases of stroke every year. One third of these patients (5 million) die and 
another one third would suffer permanent disability (Mackay & Mensah, 2004). In 
2004, stroke caused the lost of 46.6 millions of disability-adjusted life years (DALYs, 
which is equal to the years of life lost due to mortality + years lived with disability) 
(WHO, 2008), which is equal to 3.1% of global DALYs lost. The value is projected 
to take up 4.3% of the world's total DALYs lost in 2030 (WHO, 2008), which would 
make it the 4 leading cost of DALYs lost. China, with more than 1.65 million deaths 
from stroke, is on top of the death toll of individual countries (Mackay & Mensah, 
2004). Stroke accounts for about 29% of deaths in the age of 35-74 (Lloyd-Jones et 
al., 2010). It also has a DALYs lost rate of 12 per 1000 population (Mackay & 
Mensah, 2004). In Hong Kong, cerebrovascular disease accounts for about 8.4% of 
total deaths in 2009, which is the fourth leading cause of death behind cancer, heart 
disease and pneumonia (Centre for Health Protection, 2008). 
In the United States, there are on average 795,000 stroke cases per year 
(Lloyd-Jones et al., 2010). In other words, there is one stroke case happening every 
40 seconds. Stroke accounts for one in 17 deaths, and a death from stroke occurs 
every 3 to 4 minutes. In 2006, there were 6,400,000 people having had suffered from 
stroke. The rate of adult men and women who had suffered a stroke was 2.7% and 
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2.5%, respectively. 
Recurrent stroke is common after first stroke or TIA. In the United States, 23% 
of the total stroke cases, or around 185,000 cases each year, are recurrent stroke 
cases (Lloyd-Jones et al., 2010). The 5 year recurrence rate after first stroke is 13% -
28% depending on sex and age group. The consequence of recurrent stroke is much 
more severe than first stroke. The death rate for recurrent stroke is nearly doubled 
that of first stroke (Jorgensen et al., 1997). The chance of developing dementia is 
also higher after recurrent stroke than after first stroke (Pendlebury & Rothwell, 
2009). 
Since patients usually need long term rehabilitation, stroke-related medical care 
causes a great burden on the economy worldwide. It accounts for 2 - 4% of total 
spending on healthcare (Donnan et al., 2008). In the United States, about 20% of 
stroke patients need to stay in hospital or nursing home for 3 months or longer after 
the incident (Lloyd-Jones et al., 2010). The total economic cost of stroke was 
estimated to be £ 9 billion in the United Kingdom in 2005 (Saka et al., 2009), and 
US$73.7 billion in the United States in 2010 (Lloyd-Jones et al., 2010), equaling 
about 0.5% of the total gross domestic product (GDP) of both countries (Central 
Intelligence Agency, 2007, 2011). 
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1.3 Risk factors and symptoms 
There are hundreds of risk factors reported to be associated with stroke (Mackay 
& Mensah, 2004). Many of the risk factors are similar to those of coronary heart 
disease and other cardiovascular diseases. They can be classified into non-modifiable 
risks and modifiable risks. 
1.3.1 Non-modifiable risks 
Age is an important non-modifiable risk linked with stroke. The risk of stroke 
doubles for every 10 years of age after 55 (Mackay & Mensah, 2004), and the 
majority of ischemic stroke occurs in patients older than 65 (Sacco, 1997). It is 
reported that the per 1,000 rate of stroke increases from 0.6 to 2.9 (for male) and 
from 0.2 to 2.9 (for female) for the age group of < 45 and 55 — 62, respectively 
(Kannel, 1971). Race is another factor determining the risk of stroke. It is shown that 
African-Americans have higher stroke mortality rate than other ethnic groups. 
Moreover, the age of black and Hispanic stroke patients are found to be lower than 
white people (Sacco et al., 1995). African-Americans and Asians are also having 
higher risk of intracerebral occlusion (Caplan et al., 1986). The increased risk in 
black people has been associated with the higher rate of cigarette smoking (Inzitari et 
al., 1990). Moreover, diabetes is more prevalent in black people (Hajat et al, 2001), 
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and they are shown to have genetic predisposition to hypertension (Baker et aL, 
1998). However, these factors for ethnic difference still need further investigation 
(Hajat et al., 2001). Risk in men is reported to be higher than women in different 
studies (Sacco, 1997; Thorvaldsen et al., 1997). This might be due to the effects of 
estrogen on decreasing cerebral vascular tone and increasing blood flow (Krause et 
al., 2006). Cigarette smoking is more prevalent in men, contributing to the risk of 
stroke (Appelros et aL, 2009). It might also be because women have a better 
knowledge and are more aware of the prevention of stroke (Stroebele et aL, 2011). 
However, there is still no definite answer yet (Appelros et al., 2009). The risk of 
stroke increases by about one fold for a family history of stroke in a close relative 
(Liao et aL, 1997). Children with sickle cell disease also have increased risk of 
having early stroke, which happens in about 10% patients (Ohene-Frempong et al., 
1998). 
1.3.2 Modifiable risks 
Hypertension is the most important modifiable risk of stroke. In a study 
observing people undergoing a blood pressure reduction regimen, 5-year total stroke 
rate is reduced by 35% and fatal stroke by 44% (Hypertension Detection and 
Follow-up Program Cooperative Group, 1982). Moreover, various anti-hypertensive 
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drugs demonstrate stroke prevention effects. A reduction of systolic pressure by 
about 10 mmHg and diastolic pressure by about 5 mmHg by diuretics or calcium 
channel blockers reduce risk of stroke by 35% to 42%. (SHEP Cooperative Research 
Group, 1991; MRC Working Party, 1992; Staessen et al., 1997). 
Hyperlipidemia is another important risk factor. Statins are shown to lower the 
serum levels of total cholesterol, low-density lipoprotein (LDL) and triglyceride, and 
at the same time reducing risk of stroke by more than 30% (Scandinavian 
Simvastatin Survival Study Group, 1994; Sacks et al., 1996; Plehn et al., 1999). 
Stroke risk is increased by 155% in cigarette smokers, and the risk reduces to 
normal at 5 years after quitting smoking (Kawachi et al., 1993). In another study, it is 
shown that smoking can even double the risk of stroke, regardless of the amount of 
cigarettes smoked every day (Haheim et al., 1993). Heavy drinking is also found to 
increase the risk of stroke, while moderate intake of alcohol could help in preventing 
stroke (Mukamal et al., 2005; Bos et al, 2010). 
As like cardiovascular diseases, physical activity, diet and obesity are important 
risk factors. It has been shown that moderate amount of physical activity could help 
reduce the risk of stroke (Wannamethee & Shaper, 1992; Haheim et al., 1993), and 
the effect is general for different age and ethnic groups (Sacco et al., 1998). However, 
too much vigorous activity may increase the risk of hemorrhagic stroke (Lee et al, 
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1999). Increasing body mass index is significantly linked with increased stroke risk. 
The risk of overweight and obese people is doubled as compared to people with 
normal body mass index (Abbott et aL, 1994). High fat and high meat diets are 
related to increased risk of stroke (O'Donnell et aL, 2010). High fat diet may also be 
connected to other factors like hypertension and hyperlipidemia (Boden-Albala & 
Sacco, 2000). High salt and low potassium intake also raises stroke risk (Appel et aL, 
2006), possibly through raising the blood pressure. Stroke risk is higher for people 
taking less fruits and vegetables (He et al., 2006), milk, carotene, vitamin C and 
vitamin E (Gey et al., 1993; Abbott et al., 1996; Daviglus et al., 1997; Benson et al., 
1999). 
Patients with certain diseases are at high risk to stroke. Diabetic patients have a 
stroke risk increased by 1.8 fold to 6 fold (Goldstein et al., 2011). The risk of 
thromboembolic stroke increases with the blood glucose level (Burchfiel et al., 1994). 
Stroke patients with diabetes are shown to be younger and with a higher mortality 
rate compared with non-diabetic patients (Jorgensen et aL, 1994). Atrial fibrillation is 
a common source of brain embolism (Caplan, 2000). It is present in 17 — 18% of 
stroke patients (Sandercock et al., 1992; Jorgensen et aL, 1996) and it can increase 
the stroke risk by 4 - 5 fold (Kannel & Benjamin, 2008). It is also shown that stroke 
patients with atrial fibrillation suffer with larger infarcts, more severe disability and 
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higher mortality (Kimura et al., 2005; Tu et al., 2010). 
1.3.3 Symptoms 
The symptoms of stroke vary, depending on the position and amount of the 
brain tissues affected. As mentioned above, common symptoms for one suspecting to 
have a stroke include sudden facial paresis, ataxia, aphasia, hemiparesis, hemianopia, 
etc. (Goldstein & Simel, 2005). A quick diagnosis of stroke, the Face Arm Speech 
Test (FAST) assesses facial asymmetry, arm weakness and speech disturbance as 
symptoms for stroke (McArthur et al, 2011). 
Anterior cerebral artery (ACA) occlusion, which is often accompanied by MCA 
occlusion, results in hemiparesis of the limbs, particularly the legs. Occlusion of the 
left ACA may also affect speech and lead to aphasia (Roach et al., 2010). Occlusion 
of the MCA would produce infarct in the internal capsule and striatum of basal 
ganglia, which would result in deep hemiplegia, hemianopia and hemisensory loss. 
Moreover, the damage in the cortex would result in hemispatial neglect. Global 
aphasia would also happen if the occlusion happens at the left MCA (Caplan, 2000; 
Roach et al., 2010). For posterior cerebral artery (PCA) occlusion, the occipital lobes 
would be affected. Symptoms regarding eyesight, like loss of sight or color 
perception would appear. Loss of sensory perception (Pessin et al., 1987) might also 
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happen. For hemorrhagic strokes, some characteristic symptoms are often seen, 
including headache, vomiting and loss of consciousness (Caplan, 2000), because of 
the increased intracranial pressure formed by the leakage of blood. 
1.4 Mechanisms of cell injury 
1.4.1 Energy failure and loss o f ionic homeostasis 
The metabolic rate of the brain is high. Yet, the brain has only little energy 
storage. It requires continuous supply of glucose and oxygen through the 
bloodstream for aerobic metabolism to release the energy required for functioning. 
The normal blood flow rate required is about 50 ml per 100 g brain tissue per minute 
(Sharbrough et al., 1973; Trojaborg & Boysen, 1973). When ischemia occurs, the 
supply of blood, hence glucose and oxygen, is disrupted. Within minutes, the neurons 
will be deprived of energy. This will cause the transmembrane ion pumps to stop 
functioning. In particular, the Na+/K+-ATPase is important for maintaining proper 
ionic homeostasis across the cell membrane. This ion transporter helps to maintain 
the high intracellular potassium ion concentration as well as the low intracellular 
sodium ion concentration. Without enough energy supply, it fails to function. 
Membrane depolarization occurs as potassium ions flow out of the cell and sodium 
ions flow into the cell. This would trigger the influx of calcium ions through 
2‘） 
Chapter 1 Introduction 
voltage-sensitive Ca^^ channels, which in turn stimulates the release of the excitatory 
neurotransmitter glutamate. Moreover, as the high extracellular JC+ concentration is 
persisted, it leads to the depolarization of adjacent neurons, and the effect would 
extend further away, causing a phenomenon termed spreading depression (Dugan & 
Choi, 1999). 
At the same time, the neurons shift to depend on anaerobic metabolism for 
energy supply, which lead to the build up of lactic acid and hence a decrease in 
intracellular pH value (lactic acidosis). The high extracellular K+ concentration, high 
intracellular Na+ concentration, and low intracellular pH all contribute to an 
unfavorable condition for glutamate reuptake, as the reuptake couples with an intake 
of Na+ and H+, and an expulsion of K+ (Grewer & Rauen, 2005). As a result, a high 
extracellular concentration of glutamate is maintained and this causes continuous 
firing of the neurons. 
1.4.2 Excitotoxicitv and calcium-modulated cell damage 
2+ 
Membrane depolarization leads to Ca influx, which further lead to massive 
release of glutamate. The hindering in glutamate reuptake means a high extracellular 
glutamate concentration is maintained. This high extracellular glutamate 
concentration would trigger a cascade of events which are toxic to the neurons. 
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Glutamate binds to N-methyl-D-aspartic acid (NMDA) receptors, 
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) / kainic acid (KA) 
receptors, as well as metabotropic receptors (Mehta et al., 2007) to trigger neuronal 
firing. The rise in concentration of extracellular glutamate by up to 1,000 fold during 
ischemia (Dugan & Choi, 1999) would cause over-stimulation and death of the 
neurons. 
When glutamate binds to NMDA and AMPA/KA receptors, it triggers opening 
• 2 + _j_ of the ion channel and further influx of Ca and Na ions, respectively. Moreover, 
2+ 
Ca ions enter the cell through voltage-gated channels. Due to the high intracellular 
concentration of Na+, the NaVCa^ "^  ion exchangers are reversed and pumping in even 
more Ca^^ ions (Yu & Choi, 1997). As a result, Ca^ level in the cells build up 
quickly and causes a number of cytotoxic effects. Ca^^ could activate various 
catabolic enzymes, including proteases, phospholipases and endonucleases (Choi, 
1995), which break down the cell membrane, cytoskeleton, as well as DNA. Ca^^ 
influx also activates various lipid kinases and protein kinases, including protein 
kinase C, which again stimulates NMDA and AMPA/KA receptors, and opening of 
voltage-gated Ca^^ channels and lead to more influx of Ca^. On the other hand, 
stimulation of NMDA receptors would cause the activation of neuronal nitric oxide 
synthase (nNOS), which generates nitric oxide (NO). NO would react with other 
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reactive oxygen species (ROS) to generate the highly reactive free radical 
peroxynitrite (ONOO ) (Beckman & Koppenol, 1996), which attacks lipids and 
causes lipid peroxidation (Brookes et al., 1998) and cell membrane disruption. Ca^ ^ 
also activates phospholipase A2, which catalyzes the cleavage of phospholipids to 
release arachidonic acids. Free radicals are produced upon downstream metabolism 
of arachidonic acids into eicosanoids (Bazan, 1999). 
1.4.3 Oxidative stress 
Oxidative stress is a significant pathway of cell damage in ischemia. It is 
defined as a condition in which the physiological balance of oxidants and 
anti-oxidants is disturbed, in favour of the production of oxidants, which may lead to 
a potential damage (Sies, 1985). The brain is vulnerable to oxidative damage because 
of its high content of lipids and polyunsaturated fatty acids in the lipid molecules 
(Dugan & Choi, 1999; Mehta et al., 2007). Various types of free radicals, namely, 
hydrogen peroxide, hydroxyl radical, superoxide, nitric oxide, peroxynitrite, are 
generated by different mechanisms during ischemia-reperfusion (IR). Different 
cellular targets including cell membranes, mitochondria and DNA are attacked and 
lead to cell death. Moreover, free radicals could inhibit glutamate reuptake by 
oxidizing the glutamate transporter 1, excitatory amino acid transporter (EAAT)-2 
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and EAAT-3 (Trotti et al., 1997), promoting excitotoxicity. The blood brain barrier is 
also disrupted by attack of radicals on endothelial cells and astrocytes (Hall et al, 
1996). 
The mitochondria are a major source of free radicals. Adenosine triphosphate 
(ATP) generation in the mitochondria is mediated in the electron transport chain 
through different oxygen radicals, which may leak out. Under normal conditions, 
there may be 3% of the mitochondria oxygen usage being leaked out as free radical 
(Dugan & Choi, 1999). Excitotoxicity may lead to elevated mitochondrial free 
radical release. Under ischemic conditions, mitochondrial electron transport is 
2+ + 
disturbed by the high intracellular Ca and Na concentrations, leading to inhibition 
of the complex I and release of semiquinone, which further reacts with oxygen to 
I 
form superoxides. High concentration of Ca also causes mitochondrial permeability 
transition pores to open, mitochondria swelling and destmcting the mitochondrial 
membrane. Further free radical release will take place (Warner et al., 2004). 
and calmodulin activates the nNOS, leading to the production of nitric 
oxide radical, which reacts with superoxide to form the peroxynitrite radical. 
Peroxynitrite could target lipids and cause lipid peroxidation and damage the cell 
membrane. Moreover, peroxynitrite oxidizes DNA base pairs and causes DNA 
breakage (Giovannelli et al., 2002). DNA breakage in turn stimulates the activity of 
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poly(ADP-ribose) polymerase (PARP) for repairing (Warner et al., 2004), which 
would further deplete cellular ATP for producing the ADP-ribose polymer. 
Peroxynitrite could also nitrosylate the tyrosine in proteins, forming nitrotyrosine. A 
number of enzymes, including the anti-oxidative enzymes Cu/Zn-superoxide 
dismutase and Mn-superoxide dismutase, and cytochrome c oxidase (mitochondrial 
complex IV) (Dugan & Choi, 1999; Mehta et al., 2007), could be inactivated by 
nitrosylation, hence depleting the anti-oxidative ability of the cells and causing 
mitochondrial dysfunction, which would enhance the release of free radicals. 
2+ 
Ca influx activates phospholipase A2 (Clark et al., 1991), which catalyzes the 
breakdown of lipid molecules to produce arachidonic acids. Arachidonic acid is 
further metabolized to produce a group of chemicals, the eicosanoids, which are lipid 
signalling molecules including prostaglandins and thromboxane A2. The production 
of eicosanoids is catalyzed by enzymes such as the cyclooxygenases and 
lipooxygenases (Gaudet et al., 1980), and coupled with the release of free radicals, 
particularly superoxide. Moreover, the large amount of free fatty acids released 
provides targets for the radicals. When the radical attacks a lipid molecule, it 
combines with the lipid to form lipid radicals and peroxyl radicals (Chembini et al.’ 
2005), which are capable of attacking other lipid molecules, resulting in a chain 
reaction which could damage cellular membranes (Watson et al., 1984). 
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Reperflision is a state that blood could flow through the previously occluded 
vessels again. At this stage, a massive amount of free radicals are generated. As the 
anti-oxidative defence mechanisms of the brain may have already been disrupted 
during the ischemic period, it could be particularly susceptible to free radical damage 
during the reperfusion stage (Yu et al., 2008). 
1.4.4 Inflammation 
Inflammation is a very broad range of responses which may last for several days 
after ischemia. When ischemia occurs, various pro-inflammatory cytokines are 
released, typically, interleukin (IL)-la, IL-ip, IL-6 and tumor necrosis factor 
(TNF)-a. These cytokines aim to up-regulate the expression of different adhesion 
molecules, including E-selectin, inter-cellular adhesion molecule (ICAM)-l, ICAM-2 
and vascular cell adhesion molecule (VCAM)-l, which promote the recruitment of 
leukocytes to the ischemic site to repair the damaged cells (Huang et al., 2006). 
However, these cytokines may exert a number of deleterious effects to the cells. For 
example, IL-1 is associated with the induction of fever, arachidonic acid production, 
enhancement of NMDA-mediated excitotoxicity and stimulation of nitric oxide 
synthase (Huang et al., 1994). IL-6 up-regulation has also been linked with increased 
infarction (Tarkowski et al., 1995). TNF-a is associated with the disruption of the 
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blood-brain barrier (Feuerstein et al., 1994), as well as apoptosis triggering via the 
extrinsic transmembrane receptor-mediated pathway (Dugan & Choi, 1999). 
Expressions of various adhesion molecules are up-regulated, including the 
selectins, integrins and immunoglobulin supergene family adhesion molecules. 
Selectin molecules include the E-, L- and P-selectins. They are responsible for the 
low-affinity binding of platelets and leukocytes to endothelium, which facilitate the 
rolling of leukocytes. The integrin family consists of the CD lib/CD 18, and 
CDlla/CD18 molecules, which are expressed in leukocytes and for tight binding to 
the endothelium counter-receptors of ICAM-1 and ICAM-2, which are of the 
immunoglobulin supergene family. The promotion of leukocyte recruitment may 
pose injury to the neurons. Neutrophils are shown to release the matrix 
metalloproteinase-9 (MMP-9) (Justicia et al., 2003), which could damage the 
blood-brain barrier. Leukocytes would also release free radicals and proteolytic 
enzymes (Ivanova et al., 2002; Justicia et aL, 2003; Chou et al., 2004) after their 
arrival at the ischemic site, which further damage the ischemic tissue. Moreover, 
massive attachment of leukocytes and platelets to endothelium would lead to 
obstruction of the blood vessel, causing secondary ischemia. 
2‘） 
Chapter 1 Introduction 
1.4.5 Apoptosis 
Apoptosis is the process of programmed cell death. It takes place mainly in the 
ischemic penumbra (Sharp et al., 2000), since the cells in the penumbra region may 
still have enough energy release required by the process. Apoptosis is mediated 
through two main pathways, the extrinsic pathway and the intrinsic pathway, both of 
which are initiated in IR. 
The cytokine TNF-a, secreted during inflammation process following IR, 
initiates the extrinsic pathway (Dugan & Choi, 1999) by binding to the TNF receptor 
or Fas receptor on the cell membrane (Jin et aL, 2001; Mehta et al., 2007). The 
receptor undergoes trimerization and recruits the adapter molecules such as TNF 
receptor-associated death domain protein (TRADD) or Fas-associated death domain 
protein (FADD). This causes the activation of caspase 8, which in turn activates 
caspases 3, 6 and 7, and further activation of caspase-activated deoxyribonuclease 
(CAD), which catalyzes DNA fragmentation (Lopez-Neblina et al., 2005). 
The intrinsic pathway is activated by disturbance of the mitochondrial 
2+ 
membrane, which may be caused by free radical damage, energy depletion, and Ca 
overload (Dugan & Choi, 1999; Lopez-Neblina et al., 2005). Upon membrane 
disruption, the translocation of the Bcl-2-associated X (Bax) protein into the outer 
mitochondrial membrane causes the release of cytochrome c into the cytosol. 
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Cytochrome c causes the oligomerization of the apoptotic protease-activating factor 
1 (Apaf-1), which then combines with cytochrome c, deoxyadenosine triphosphate 
(dATP) and procaspase 9 to form the apoptosome. Caspase 9 is activated and 
catalyzes further activation of caspases 3, 6 and 7 and lead to DNA fragmentation 
(Zou et al., 1999; Lopez-Neblina et al., 2005). 
1.5 Current treatment of ischemia 
Treatment of ischemia is focused on preserving neurons in the penumbra region. 
There are two major directions for treatment, restoring perfusion in the area and 
reducing cell injury (neuroprotection) (Walz, 1999; Bhuiyan & Kim, 2010). 
Restoring blood flow is critical for preventing ischemic injury progression. The 
thrombolytic drug, tissue plasminogen activator (tPA), is the only drug approved by 
the United States Food and Drug Administration (USFDA) for stroke treatment 
(Maestre-Moreno et al, 2005). It is a serine protease which activates plasminogen 
into plasmin. The plasmin then digests the fibrin in a blood clot and the blood clot is 
dissolved. Intravenous application of tPA is a fast and simple method to lyse 
thrombus and restore blood flow. tPA has been shown to improve the long-term 
outcome of stroke, introducing a 32% decrease in disability after 3 months of stroke 
in a study, as compared to the placebo group (National Institute of Neurological 
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Disorders and Stroke rt-PA Stroke Study Group, 1995). However, the patients have 
10 times higher intracerebral hemorrhage risk within 36 hours after treatment than 
the placebo group. Therefore, tPA is not suitable for a number of patients such as 
those with hemorrhage history, or with high blood pressure. Moreover, tPA has to be 
applied within a short time window of 3 hours within stroke onset, although some 
studies show that application at 4.5 hours after onset is still effective (Hacke et al., 
2008; Del Zoppo et al., 2009). Other anti-coagulating drugs like heparin is also 
found to be effective in clinical trials (Kay et al.’ 1995). Mechanical intervention to 
remove the clot has been demonstrated effective, with the MERCI (Mechanical 
Embolus Removal in Cerebral Ischemia) catheter approved by the USFDA for clot 
removal. However, the use of this method is only limited because the mortality is still 
high (Smith et al., 2005; Roach et al., 2010). On the other hand, use of ultrasound 
has been shown to improve the effect of tPA in helping blood reflow by up to 60% 
(Alexandrov et al., 2004). 
Neuroprotective agents can target on various pathways along the ischemic 
cascade. Calcium ion channel blockers, such as nimodipine and nitrendipine, has 
been suggested as potential neuroprotective agents (Staessen et al，1997; Tomassoni 
el al., 2008). NMDA / AMPA / KA receptor antagonists have also been suggested as 
potential candidates (Roach el al., 2010). Numerous anti-oxidants have been 
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demonstrated in animal experiments as neuroprotective against ischemia. However, 
no neuroprotective drug has been approved by the USFDA for acute ischemic stroke 
yet (Roach et 
1.6 Chinese herbal medicine 
1.6.1 Traditional Chinese medicine theory on stroke 
Chinese medicine works under a holistic approach which considers the human 
body in a close relationship with the environment. The normal body should be in a 
state of balance; if the balance is lost, diseases would happen (Gong & Sucher, 1999). 
Stroke is generally equal to the syndrome of ‘wind stroke' in Chinese medicine 
(Sucher, 2006). In traditional Chinese medicine theory, wind stroke is caused by 
'wind evils', which associates with overwhelming 'Yang' and loss of body 
‘Yin-Yang’ balance. ‘Wind evils' build up during kidney and liver malfunctioning, 
emotional disturbance and stress, over-consumption of food and drink, as well as 
aging (external winds), which causes liver fire and phlegm accumulation in the body 
(internal winds) and 'Qi' and blood stagnation, leading to serious illness (Gao et al, 
2004). 
Diagnosis of Chinese medicine is based on the four techniques of inspection, 
auscultation and olfaction, interrogation and palpation (Hsiao ct al.，2008). When 
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‘wind stroke' happens, symptoms including facial paralysis, dysphasia, and 
hemiplegia occur (Gong & Sucher, 1999). A ‘choppy’ pulse could be detected, which 
is a characteristic slow, stagnant, relaxed and irregular pulse, with 3 - 5 pulses per 
respiration (Flaws, 1995). 
Treatment is based on expelling the external winds and calming the internal 
winds. More than 100 herbs had been used in formulae for stroke (Sucher, 2006) 
according to body conditions of individual patients. Multiple herbs were used in the 
formulae to gain the advantages of inducing synergistic effects, ameliorating adverse 
effects, as well as targeting multiple symptoms at the same time. The herbs Danshen 
and Gegen were found among the traditional formulae used for ‘wind stroke'. 
1.6.2 Danshen 
Danshen is the dried root of the plant Salvia miltiorrhiza Bunge, which is a 
deciduous plant of the family of Labiatae (Lam et aL, 2006). It is traditionally used 
in China as a treatment for cardiovascular diseases. According to the Chinese 
Pharmacopoeia, Danshen is bitter in taste and slightly cold in nature. It has the 
effects of activating circulation, dispersing stasis or sludging of blood (Cheng, 2007), 
clearing heat from the blood, resolving swelling, and tranquilizing the mind (Chan et 
al, 2004). It is widely used in formulae or on its own for various cardiovascular 
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diseases such as angina, hypertension and coronary heart disease. 
Various hydrophilic and lipophilic pure compounds have been purified from 
Danshen. The hydrophilic compounds consist of mainly phenolic acids (Zhou et al, 
2005) including salvianolic acid A, salvianolic acid B, danshensu and lithospermic 
acid B. Lipophilic compounds are mainly diterpene compounds, including the 
various tanshionone compounds. 
Both Danshen raw extract and pure compounds showed wide range of effects 
towards cardiovascular and cerebrovascular complications. Danshen extract was able 
to protect cardiac cells from myocardial infarction and reduce mortality, and protect 
neurons from cerebral ischemia (Kuang et al., 1993; Wu et aL, 1997; Lao et al., 
2003). Danshen also acted as a calcium antagonist, which could help reduce 
excitotoxicity during ischemia as well as reduce coronary artery spasm (Chen, 1981). 
The pure compound, salvianolic acid B, also demonstrated neuroprotective effects 
against cerebral ischemia (Chen et aL, 2000). 
Danshen extract was demonstrated to improve microcirculation, reduce blood 
viscosity and promote angiogenesis in coronary patients (Jin, 1978), and reduce 
blood pressure and cholesterol level in humans (Wang & Zhao, 2003). Salvianolic 
acid A and magnesium tanshinoate B were found to inhibit LDL oxidation (O ct al., 
2001 ； Liu & Liu, 2002), and lithospermic acid B was also found to induce vessel 
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relaxation in the aorta ring model (Kang et aL, 2003). For platelet aggregation, both 
salvianolic acid B (Yao et al., 2008) and danshensu (Li, 1983) were able to inhibit 
ADP-induced platelet aggregation. 
Danshen also exerted effects on anti-inflammation in in vitro models. Aqueous 
extract was found to reduce E-selectin, ICAM-1 and VCAM-1 levels in human 
umbilical vein endothelial cells (HUVEC) (Ren et aL, 2002). Salvianolic acid B was 
able to inhibit monocyte-endothelial cell binding, reduce ICAM-1 and VCAM-1 
expressions and nuclear factor kappa-light-chain-enhancer of activated B cells 
( N F - K B ) activation (Chen et al, 2001). Tanshinone IIA was able to inhibit inducible 
nitric oxide synthase (iNOS) protein production, and reduce IL-ip, IL-6 and TNF-a 
levels in RAW 264.7 cells (Fan et al., 2009). 
In addition, Danshen acted through anti-oxidation pathways. Danshen aqueous 
extract was shown to reduce ROS (Lao et al., 2003) and malondialdehyde (MDA) 
(Liu et aL, 2006a) levels, and increase catalase, superoxide dismutase (SOD) and 
glutathione activities in rat brains after ischemia (Mo et aL, 1998). Salvianolic acid B 
was shown to scavenge hydrogen peroxide, hydroxyl radical and superoxide in in 
vitro models (Zhao el al., 2008). Danshensu and tanshinone IIA were also 
demonstrated to scavenge free radicals in myocardial mitochondria during IR (Zhao 
el al., 1996). 
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Previously, it was shown that pure compounds such as danshensu and 
protocatechuic acid was able to pass through the blood-brain barrier (Zhang et al., 
2011), while salvianolic acid B crossed it less effectively (Xu et al., 2007a). The 
lipophilic compounds of tanshinone IIa (Lam et al, 2003) and tanshinone lie (Yu et 
al” 2007) also crossed the blood-brain barrier effectively. 
1.6.3 Gegen 
Gegen is the dried root of the plant Pueraria lobata (Willd.) Ohwi, which is a 
leguminous vine of the family of Fabaceae. Gegen had a long history of being used 
in Chinese medicine and is widely used either as a single herb or in formulae. It is 
cool in nature, and sweet and acrid in taste. According to the Chinese Pharmacopoeia, 
Gegen has the effects of increasing 'yang', stopping diarrhea, relieving thirst and 
fever, encouraging production of body fluid, treating dysentery, flu, as well as 
hypertension. In addition, Gegen was traditionally used as a treatment for 
cardiovascular diseases and diabetes mellitus. In recent studies, Gegen was shown to 
be beneficial towards Alzheimer's disease (Choi et al., 2010; Li et aL, 2010). 
A number of bioactive pure compounds have been purified from Gegen, with 
most of them being isoflavonoids, including puerarin, daidzin, daidzein, etc. Among 
these, puerarin was the first being identified and the most studied. It possesses a wide 
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range of beneficial effects towards cardiovascular and cerebrovascular complications, 
as well as diabetes (Wong et al., 2011). 
For cardiovascular diseases, puerarin was shown to reduce blood pressure and 
heart rate in spontaneously hypertensive rats (SHRs) (Song et al., 1988) and cats (Lu 
et al., 1987). In aortic ring models, puerarin demonstrated vasodilative effects 
through both endothelium-dependent pathways by inducing nitric oxide production 
(Sun & Li, 2002), and endothelium-independent pathways by modulation of 
potassium channels (Dong et al., 2004). Puerarin also protected cardiomyocytes from 
ischemia (Gao et al.’ 2006), inhibited platelet aggregation (Liu et al., 2006b), and 
promoted angiogenesis (Zhang et al., 2006b). 
As for cerebral ischemia, puerarin protected primary hippocampal neurons 
against oxygen-glucose deprivation (OGD) by inhibiting apoptosis, calcium ion 
influx and NO synthesis (Xu & Zheng, 2007; Xu et aL, 2007b). Puerarin also 
protected cerebral cortical neurons from glutamate, NMDA and KA induced 
toxicities (Dong & Wang, 1998), and inhibited apoptosis in PC-12 cells induced by 
H2O2 (Jiang et al., 2003) and P-amyloid (Zhang et aL, 2008). In in vivo models, 
puerarin was able to improve neurological functions and reduce brain infarct and 
edema volume in rats after middle cerebral artery occlusion (MCAO) (Xu et al., 
2005; Chang el aL, 2009). Puerarin could also decrease the concentrations of 
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intracellular Ca , and extracellular glutamate, aspartate, y-aminobutyric acid 
(GABA) and taurine (Xu et al., 2007b), hence reducing excitotoxicity. Puerarin also 
had the effects of inhibiting apoptosis by down-regulating caspase 3 (Xu et aL, 2005), 
and inhibiting inflammation by lowering the expressions of TNF-a, iNOS and N F - K B 
translocation in ischemic rats (Ding et al, 2007; Chang et al，2009). It was shown in 
previous studies that puerarin readily crossed the blood-brain barrier (Prasain et al, 
2004; Yan et al, 2006). 
Other than ischemia, puerarin was also beneficial to diabetes by reducing blood 
glucose level in diabetic rats (Chen et al., 2004), inhibiting vascular smooth muscle 
cell (SMC) proliferation, reducing systolic blood pressure, serum glucose, total 
cholesterol and triglyceride levels (Zhu et al., 2010). 
Other than puerarin, compounds like daidzein and genistein were able to reduce 
inflammation by lowering the release of arachidonic acid in macrophage cells (Jun et 
al., 2005). Puerarin, puerol B and puerariafuran were able to inhibit the formation of 
advanced glycation end-products (Jang et aL, 2006; Kim et aL, 2006), which are 
involved in inflammatory diseases. Daidzin and daidzein were also shown to inhibit 
platelet aggregation induced by collagen and ADP (Choo et aL, 2002). In addition, 
genistein and biochanin A were able to protect cells against P-amyloid-induced 
toxicity (Choi t" a/., 2010). 
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1.6.4 Danshen-Gegen formula 
Danshen, Gegen and Yanhu (Corydalis Rhizoma) in the ratio of 6:3:1 (w/w) was 
recorded in the ‘Zhong Yao Fang Ji Xian Dai Yan Jiu Da Dian'(中藥方齊J現代硏究 
大典)(Huang & Shi, 1996) as the simplest formula for treatment of cardiovascular 
diseases. However, as the effect of Yanhu was mainly analgesic, it may mask the pain 
during angina or coronary heart disease and hence cause danger to patients taking 
this formula. Moreover, Yanhu did not possess much cardiovascular effects. As a 
result, Yanhu was excluded from the formula. The part of Yanhu was replaced by 
Danshen to become the 7:3 formula. A free radical scavenging test was carried out to 
screen for the most potent combination of Danshen and Gegen, as free radical attack 
represented an initial step in the formation of atherosclerosis, and hence subsequent 
diseases like ischemia and coronary heart attack (Leung, 2003). From the results, 
Danshen-Gegen 7:3 (w/w) water extract formula demonstrated the most potent 
protective effect on 2,2'-azo-bis-(2-amidinopropane) dihydrochloride (AAPH) 
-induced red blood cell hemolysis, as compared to the 2:1 or 1:1 formulae. Therefore, 
Danshen-Gegen 7:3 (DG) extract was chosen for further studies. In the subsequent 
clinical trial, DG extract was shown to significantly improve the flow-mediated 
dilation of brachial artery as well as decrease the intima-media thickness in treatment 
sub) eels as compared with thai of the placebo group (Tarn et al., 2009). 
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DG extract had also shown different cardiovascular tonic effects in previous 
studies. Its anti-oxidative effect was shown on inhibiting AAPH-induced red blood 
cell hemolysis and cardiomyocyte death, and calcium ion induced LDL oxidation 
(Koon, 2006). It could also increase plasma levels of total anti-oxidants, SOD, 
catalase and glutathione peroxidase (GPX) (Wong, 2007). 
DG extract could also protect cardiac cells from IR, and recover the contractile 
force and coronary flow rate (Leung, 2003). Its vasodilative effects via both 
endothelium-dependent and endothelium-independent pathways were demonstrated 
using the aorta ring model. Moreover, the anti-atherosclerotic effects of DG extract 
were demonstrated via the inhibition of vascular SMC proliferation and migration, 
endothelial-monocyte cell adhesion (Koon, 2006), and foam cell formation 
(Sieveking et a/., 2005). 
To summarize, Danshen-Gegen 7:3 water extract possessed cardiovascular 
effects of anti-oxidation, protection of heart against ischemia-reoxygenation, 
vasodilation and anti-atherosclerosis. These effects are also potentially beneficial for 
cerebrovascular diseases such as stroke. Therefore, DG extract is further investigated 
for its neuroprotective effects. 
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1.7 Aim of study 
Since DG extract has demonstrated various cardiovascular tonic effects, it may 
also be potent towards cerebrovascular diseases. The present study aimed at 
evaluating the protective effects of DG extract towards cerebral ischemia. The 
following studies would be carried out: 
1. To evaluate the protective effect of DG extract on neuronal cells after IR using 
an in vivo transient focal ischemia model to mimic the condition of cerebral 
stroke. 
2. To evaluate the effect of DG extract (protective as well as therapeutic) on 
memory retention after IR using a 2-way shuttle box avoidance test. 
3. To examine the anti-blood coagulation effect of DG extract since blood 
coagulation is a harmful process to stroke patients during ischemia and after 
reperfusion for the possibility of generating secondary ischemia. 
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Chapter 2 General methodology 
The whole study is divided into the following 4 major parts: 
1. Preparation of herbal medicine (Chapter 3); 
2. Protective effect of DG extract on cerebral ischemia (Chapter 4); 
3. Behavioral assessment using the shuttle box avoidance test for protective and 
therapeutic effect of DG extract treatment (Chapter 5); and 
4. Anti-blood coagulation effect of DG extract (Chapter 6). 
The detailed methodological procedures of various parts of the study are 
included in this chapter, including induction of transient focal cerebral ischemia, 
neurological scoring, brain infarction measurement and statistical analysis. Specific 
protocols of each experiment are referred to in the corresponding chapters: 
preparation of herbal medicine (Chapter 3), protection on cerebral infarction and 
neurological deficit (Chapter 4.2.1), anti-oxidative enzyme induction (Chapter 4.2.2), 
shuttle box avoidance test (Chapter 5.2), and anti-blood coagulation effect (Chapter 
6.2). 
2.1 Induction of transient focal cerebral ischemia by middle cerebral 
artery occlusion (MCAO) 
All the animal experimental procedures in this study were approved by the 
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Animal Experimentation Ethics Committee of The Chinese University of Hong Kong 
(AEEC project number: 06/050/MIS). License to conduct animal experiments was 
obtained from the Department of Health of the government of the Hong Kong 
Special Administrative Region (License number: (07-254) in DH/ORHI/8/2/1 pt. 10 
and (09-290) in DH/HA&P/8/2/1 pt. 8). 
2.1.1 Intraluminal filament production 
The intraluminal filament for occlusion of middle cerebral artery was prepared 
by coating approximately 5 mm of the tip of a nylon thread by silicone sealant (RTV 
coating 3140, Dow Corning, Midland, USA) to produce a rounded head and a 
smooth cylindrical body (Lourbopoulos et al., 2008). The coated filament was 
examined under a light microscope (Olympus 1X71, Olympus Corporation, Tokyo, 
Japan) and the diameter was measured by image analyzing software (SPOT 
Advanced Version 3.5.6.2 for Windows, SPOT Imaging Solutions, Sterling Heights, 
MI, USA). The diameter of the rounded tip was kept at 330 — 340 |Lim while that of 
the cylindrical body was kept at 310 — 330 i^m (Figure 2.1). The coating was dried 
under room temperature for at least 72 hours before use. A mark was made at 18-20 
mm of the filament to indicate the approximate length to be inserted into the blood 
vessel. 
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Figure 2.1 The silicone coated intraluminal filament head (about 2 mm) as seen 
under microscope (40X magnification). 
2.1.2 Cerebral blood flow measurement by laser Doppler flowmetry 
The cerebral blood flow was continuously measured by a laser Doppler 
flowmeter (PeriFlux System 5000, Perimed AB, Stockholm, Sweden). Male 
Sprague-Dawley (SD) rats of 230 - 250 g were firstly anesthetized by intraperitoneal 
injection of 400 mg/Kg chloral hydrate (VWR International Ltd., Poole, England). 
The skin over the head skull was sterilized by 70% ethanol. A sagittal midline 
incision of about 1 cm was made in the skin above the skull. The membranes lining 
the skull were cut open to expose the skull around the bregma. A probe holder (Probe 
holder PH07-6, Perimed AB, Sweden) was placed directly above the skull of the 
right cerebrum at 1 mm posterior and 2 mm lateral to bregma (Spralt ct 2006) 
(Figure 2.2). 
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Figure 2.2 Location of the laser Doppler probe holder on the right hemisphere at 1 
mm posterior and 2 mm lateral to bregma as shown in the black spot (extracted from 
GRAP, n.d.). 
The probe holder was fixed by applying glue (Loctite 4161, Henkel, Dusseldorf, 
Germany) followed by the use of an accelerator (Insta-set accelerator, Bob Smith 
Industries Inc., Alascadero, CA, USA). A laser Doppler probe (PROBE 407, Perimed 
AB, Sweden) was held by the probe holder and used to measure the cerebral blood 
flow during the whole process of the operation (Figure 2.3). The blood flow was 
measured in arbitrary units. 
P / •邏 
r i j»urc 2.3 I vocation of the probe holder on Ihc skull of the ral. 
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2.1.3 Middle cerebral artery occlusion (MCAO) 
Transient focal cerebral ischemia was induced by an intraluminal filament 
method modified from that of Longa et al (1989) (Figure 2.4). 
Right Left 
, • 、 
/ 1 
Middle cerebral artery (MCA) } r ^ 
\ / (ili)\ 
v'l w � � ^ ^ AnI. cerobrai a. 
/ / \ /、！V ！V^  cerebri] a. 
Po•丨，comm. w f / i w ^ carab/ii a. 
Sup. c»r«b«Utr • """如 
Internal carotid artery (ICA) l ^ H ^ ^ W " 如 灿 “ 
External carotid artery (ECA) IJ ‘ 
\ ^Ext. carotid a. 
T X 
J卜 Com ctfoUd a. 
Figure 2.4 The procedure of MCAO (Ventral view). The intraluminal filament was 
inserted inside the right ECA, passed through the right ICA to occlude the origin of 
the right MCA (Longa et al., 1989). 
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Figure 2.5 The trifurcation of the CCA, ICA and ECA at the thoracic region. 
The skin around the thoracic region of the rat was firstly sterilized by 70% 
ethanol. A sagittal midline incision of about 1.5 cm was made at the thoracic region. 
The right common carotid artery (CCA) and the bifurcation of the external carotid 
artery (ECA) and the internal carotid artery (ICA) were exposed (Figure 2.5). 
A 4.0 silk braided suture (Kent Scientific Corporation, Torrington, Connecticut, 
USA) was placed across the bottom of the CCA. In accidental situations, bleeding 
could be stopped by picking up this suture. Then, the branch vessel from the right 
I>CA and the bridge vessel between ECA and ICA were isolated and ligated by 
cautcry (Gemini Cautery System, BIOSl^ ^B, Vilrollcs, iMancc). The 1 丄C八 was lied by 
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a 4.0 silk braided suture and then ligated by cautery at the far end from the ECA-ICA 
bifurcation. A 5.0 silk braided suture (Kent Scientific Corporation, USA) was placed 
across the tied stump of ECA for holding the intraluminal filament. The CCA and 
ICA were then clamped by micro bulldog clamps (World Precision Instruments Inc., 
Sarasota, FL, USA) and a transverse incision was made at the ECA stump by a pair 
of Vannas scissors (World Precision Instruments Inc., USA). The intraluminal 
filament was inserted into the ECA from the incision and pushed into the ICA. The 
clamp on the ICA was released and the filament was further inserted for around 18 -
20 mm until a drop of ^ 60% of the cerebral blood flow in arbitrary units was 
observed, which indicated successful blockage of the origin of the MCA. The 5.0 
suture around the ECA was tightened to hold the intraluminal filament and prevent 
bleeding. The clamp on CCA was then released and the filament was held in position 
for 2 hours. The opening was covered by a piece of cotton soaked in saline to prevent 
dehydration. Chloral hydrate was injected intraperitoneally at 70 mg/Kg every 45 
minutes to maintain anesthesia. 
After 2 hours of ischemia, reperfusion was achieved by withdrawing the 
filament from the ICA. The CCA was clamped by a micro bulldog clamp. The 
intraluminal filament was firstly withdrawn into the ECA stump and the ICA was 
clamped by a micro bulldog clamp. Then, the filament was pulled out through the 
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EC A incision and the 5.0 suture around the ECA was tied to stop bleeding. Both 
clamps on the ICA and CCA were then removed. The wound was applied with 
penicillin (10,000 units/ml) and streptomycin (10,000 i^g/ml) (Invitrogen 
Corporation, Carlsbad, California, USA) and closed by a surgical needle (World 
Precision Instruments Inc., USA) and 4.0 silk braided suture. The laser Doppler 
probe and probe holder were then removed and the wound at the head was sterilized 
and sutured similarly. The rat was then returned to cage and hosted individually. 
2.2 Neurological scoring 
Neurological deficit of rats suffered from MCAO was measured by a scoring 
system modified from that described by Bederson et al. (1986b). Table 2.1 and 
Figure 2.6 show the scoring system: 
Table 2.1 Neurological scores given to rats after MCAO 
Neurological score Neurological deficit shown 
0 No apparent neurological deficits 
1 Contralateral forelimb flexion when pushed to the edge of a bench 
2 Decreased resistance to lateral push to the left 
3 Contralateral circling when pulled by the tail 
4 Spontaneous circling or could not walk spontaneously 
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Figure 2.6 (a) Rats showing contralateral forelimb flexion (on the left forelimb) 
were given neurological score 1. (b) Rats showing decreased resistance to lateral 
push to the left were given neurological score 2. (c) Rats showing contralateral 
circling (circling to the left only) were given neurological score 3. 
N.B. Neurological score 4 (spontaneous circling or could not walk spontaneously) 
could not be shown using photo. 
2.3 Brain infarction measurement by triphenyltetrazolium chloride (TTC) 
staining 
Brain infarction volume was quantified by triphenyltetrazolium chloride (TTC) 
staining (Zhan & Yang, 2006). The rat was sacrificed by an overdose of chloral 
hydrate. The skull was opened and the brain was taken out. The brain was washed in 
cold phosphate-buffered saline (PBS) (Invitrogen Corporation, USA) and frozen at 
-20°C for 1.5 hours. Then, it was cut into 6 coronal slices of 2 mm thick, starting 
from 2 mm from the frontal pole (i.e., at 4 mm, 6 mm, 8 mm, 10 mm, 12 mm and 14 
mm), using a rat brain matrix (RBMA-300C, Kent Scientific Corporation, USA) 
(Figure 2.7) and matrix blades (Kent Scientific Corporation, USA). The slices were 
immersed in 2% TTC solution in PBS (Sigma-Aldrich, St. Louis, MO, USA) and 
incubated at 37()C for 20 minutes for staining. The living cells would be stained red 
while the dead cells would be retained white (Figure 2.8). The stained slices were 
then fixed in 10% neutral buffered formalin solution (Sigma-Aldrich, USA) for 1 day 
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Figure 2.7 The brain matrix used to slice the brain with l-mm cutting positions. 
The brain was put on the matrix and sliced by placing the blades into the cutting 
positions at 2-mm intervals. 
Figure 2.8 Representative photo of brain slice. Area stained in red are living cells 
while area in white are the infarcted cells. 
The images of the fixed brain slices were captured by a desktop scanner (Epson 
Perfection 1260, Seiko Epson Corporation, Nagano, Japan), with scanning software 
(Epson TWAIN 5 version 5.60E, Seiko Epson Corporation, Japan). The configuration 
of the program used is listed in Table 2.2. 
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Table 2.2 Configuration of the scanning software used for capturing images of the 
brain slices 
Image type: Color photo Highlight: 162 
Resolution: 600 dpi Shadow: 46 
Exposure: 6 Saturation: 15 
Gamma: 1.32 Grey balance intensity: 25 
The images were analyzed by image analyzing software (Adobe Photoshop CS4 
Extended Version 11.0.1, Adobe Systems Inc., San Jose, CA, USA). Areas of brain 
slices stained in red and those retaining white were identified by the software with 
55,800 pixels equal to 1 cm� . The total infarction volume was then calculated by 
multiplying the infarction area of each slice by its thickness (2 mm) and summing up 
the infarction volume of all 6 slices. 
2.4 Statistical analyses 
The differences between treatment and control groups were tested with one-way 
analysis of variance (one-way ANOVA) followed by Tukey's multiple comparison 
test for all of the experiments except specified. All statistical analyses were 
performed by using GraphPad Prism software version 5.02 (GraphPad Software, San 
Diego, California, USA) and carried out at 5% level of significance (p < 0.05). Data 
were expressed as mean 土 standard error of the mean (SEM) in all experiments. 
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3.1 Authentication of Chinese herbs 
Danshen (Salviae Miltiorrhizae Radix et Rhizoma) grown in Sichuan province 




Figure 3.1 The raw herbs of (a) Danshen and (b) Gegen used in the study. 
3.1.1 Morphological authentication 
Morphological authentication was carried out by Dr. H. Cao of the National 
Engineering Research Centre for Modernization of TCM, Zhuhai, Guangdong, China, 
according to the Chinese Pharmacopoeia 2010. Danshen was a long cylindrical root 
with slight curves (Figure 3.1a). The surface was brownish-red and rough, with 
wrinkles in longitudinal direction. It was hard and fragile, the bark portion was 
brownish-red and the wood part was grayish-yellow, with yellowish-white vascular 
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bundles. 
Gegen was cut in rectangular blocks longitudinally (Figure 3.1b). The bark was 
brown in color and rough with wrinkles in longitudinal direction. The cut surface 
was yellowish white with striations not very clear and distinct. 
3.1.2 Chemical authentication using thin layer chromatography 
Thin layer chromatography (TLC) was carried out to compare each herb with 
the reference herb as well as chemical markers as listed in Chinese Pharmacopoeia 
2010, with slight modifications. 
3.1.2.1 Danshen 
0.2 g of powdered Danshen raw herb and Danshen reference herb was dissolved 
separately in 25 ml of 75% methanol and heated under reflux for 1 hour. The 
decoctions were filtered and concentrated to 1 ml to be used in the TLC. One 
milligram of the chemical marker, tanshinone lU, was dissolved in 1 ml of methanol. 
The Danshen reference herb, raw herb and chemical marker solutions were 
applied as separate bands onto a TLC plate (Silica gel 60 F254, Merck KGaA, 
Darmstadt, Germany) at 1 cm from the bottom edge. The plate was put inside a TLC 
tank pre-saturated with the developing solution (n-hexane : ethyl acetate = 8 : 2 , 
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developing system 1). The chromatogram was developed to 8 cm in height. Then, the 
TLC plate was removed from the tank, dried and observed under visible light and 
UV 254 nm. Figure 3.2 shows the details of the TLC profile of Danshen in 
developing system 1. 
Visible light UV 254 nm 
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1: Reference herb 2: Danshen raw herb 3: Tanshinone IIA 
Plate: Silica gel 60 F254 (Merck, Germany.) 
Developing system: N-hexane : ethyl acetate = 8 : 2 
Figure 3.2 Details of the TLC profile of Danshen using developing system 1 
(n-hexane : ethyl acetate = 8 : 2 ) . TLC was carried out according to the Chinese 
Pharmacopoeia 2010 with reference herb and chemical marker tanshinone IIa. Bands 
were observed under visible light and UV 254 nm. 45 
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Then, similar procedures were carried out again, using developing system 2 
(hexane : chloroform : ethyl acetate : methanol : formic acid = 2 : 3 : 4 : 0.5 : 2), for 
another chemical marker, salvianolic acid B. The TLC plate was observed under UV 
254 nm. An indicator, 40% sulfuric acid in ethanol, was then sprayed evenly onto the 
TLC plate to visualize the bands and the plate was observed again under visible light. 
Figure 3.3 shows the TLC profile of Danshen in developing system 2. 
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Before applying indicator After applying indicator 
UV 254 mn Visible light 
I^^H^  ‘ • _ i 
1 2 3 1 2 3 
1 ： Reference herb 2: Danshen raw herb 3: Salvianolic acid B 
Plate: Silica gel 60 F254 (Merck, Germany) 
Developing system: 
Hexane : chloroform : ethyl acetate : methanol : formic acid = 2 : 3 : 4 : 0.5 : 2 
Indicator: 40% sulfuric acid in ethanol 
Figure 3.3 Details of the TLC profile of Danshen using developing system 2 
(hexane : chloroform : ethyl acetate : methanol : formic acid = 2 : 3 : 4 : 0.5 : 2). TLC 
was carried out according to the Chinese Pharmacopoeia 2010 with reference herb 
and chemical marker salvianolic acid B. An indicator, 40% sulfuric acid in ethanol, 
was sprayed evenly onto the plate to visualize the bands. The TLC profile was 
observed under UV 254 nm before applying indicator and under visible light after 
applying indicator. 
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From the results of TLC, the Danshen raw herb showed similar profiles as the 
reference herb. Moreover, the chemical markers, tanshinone IIA and salvianolic acid 
B, were present in the raw herb. Therefore, the Danshen raw herb purchased was 
found to be in compliance with the TLC test as quoted in Chinese Pharmacopoeia 
2010. 
3. J.2.2 Gegen 
0.8 g of powdered Gegen raw herb and Gegen reference herb were separately 
soaked in 10 ml of methanol for 1 hour. The mixtures were filtered and evaporated to 
dryness. The residues were separately dissolved in 0.5 ml of methanol and these 
served as the test solution of Gegen raw herb and Gegen reference herb. One 
milligram of the chemical marker, puerarin, was dissolved in 1 ml of methanol. 
The Gegen reference herb, raw herb and chemical marker solutions were 
applied as separate bands onto a TLC plate (Silica gel 60 F254, Merck, Germany) at 1 
cm from the bottom edge. The plate was put inside a TLC tank pre-saturated with the 
developing solution (chloroform : methanol : water = 7 : 2.5 : 0.25). The 
chromatogram was developed to 8 cm in height. Then, the TLC plate was removed 
from the tank, dried and observed under UV 254 nm and UV 365 nm. Figure 3.4 
shows the details of the TLC profiles of Gegen. 
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1: Reference herb 2: Gegen raw herb 3: Puerarin 
Plate: Silica gel 60 F254 (Merck, Germany) 
Developing system: Chloroform : methanol : water = 7 : 2.5 : 0.25 
Figure 3.4 Details of the TLC profile of Gegen using developing system 
chloroform : methanol : water = 7 : 2.5 : 0.25. TLC was carried out according to the 
Chinese Pharmacopoeia 2010 with reference herb and chemical marker puerarin. The 
TLC profile was observed under UV 254 nm and UV 365 nm. 
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From the results of TLC, the Gegen raw herb showed a similar profile as the 
reference herb. Moreover, the chemical marker, puerarin, was present in the raw herb. 
Therefore, the Gegen raw herb purchased was found to be in compliance with the 
TLC test as quoted in Chinese Pharmacopoeia 2010. 
Voucher specimens of both herbs were kept at the museum of Institute of 
Chinese Medicine, The Chinese University of Hong Kong, with the following 
voucher specimen numbers as listed in Table 3.1. 
Table 3.1 Voucher specimen numbers of Danshen and Gegen 
Herbs Voucher specimen numbers 
Danshen 2008-3166b 
Gegen 2008-3167b 
3.2 Danshen-Gegen (DG) extract preparation 
The herbal extracts were prepared by the National Engineering Research Centre 
for Modernization of TCM. The raw herbs of Danshen and Gegen were washed, cut 
and dried. 350 kg of Danshen and 150 kg of Gegen were mixed (7:3, w/w). They 
were soaked in water in the ratio of 1:10 (w/v) for 1.5 hours. Then, water extraction 
was carried out at 1 OO^ C for 1 hour. The extracts were collected and the herbs were 
further extracted with water in the ratio of 1:8 (w/v) twice for 1 hour and 0.5 hour, 
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respectively. All the extracts were combined and concentrated at 65°C at a pressure 
of-0.07 MPa to give the dry powder (Figure 3.5). Fifty kilograms of dry powder was 
obtained. The extraction yield was 10.0% w/w. The powder was stored at 4°C, and 
was re-dissolved in water prior to the experiments. The same batch of powder extract 
(batch number: CaoHui 27082008-H20) was used in all the experiments. 
,.，-•-•.、、二，？.“ . 
Figure 3.5 Dried powder of DG extract. 
3.3 Chemical analysis of DG extract 
After extraction, the DG extract was analyzed using TLC and high performance 
liquid chromatography (HPLC) to evaluate its chemical components. 
J.J./ TLC 
TLC was carried out to compare the extracts against reference chemical markers 
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of Danshen (salvianolic acid B and tanshinone IIA) and Gegen (puerarin). 
One hundred milligrams of dried DG extract powder was dissolved in 1 ml of 
water as the test solution. One milligram of each of salvianolic acid B, tanshinone IIA 
and puerarin was dissolved separately in 1 ml of methanol, and these were used as 
the test solution for the chemical markers. 
The DG extract and chemical marker solutions were applied as separate bands 
onto a TLC plate (Silica gel 60 F254, Merck, Germany) at 1 cm from the bottom edge. 
The plate was put inside a TLC tank pre-saturated with the developing solution (ethyl 
acetate : methanol: water = 8 : 3 : 0.5). The chromatogram was developed to 8 cm in 
height. Then, the TLC plate was removed from the tank, dried and observed under 
UV 254 nm. An indicator, 40% sulfuric acid in ethanol, was then sprayed evenly onto 
the TLC plate to visualize the bands and the plate was observed again under visible 
light. Figure 3.6 shows the details of the TLC profiles of the DG extract. 
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Before applying indicator After applying indicator 
UV 254 nm Visible light 
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1: DG extract 2: Puerarin 3: Tanshinone IIA 
4: Salvianolic acid B 
Plate: Silica gel 60 F254 (Merck, Germany) 
Developing system: Ethyl acetate: methanol: water = 8: 3: 0.5 
Figure 3.6 TLC chromatogram of DG extract against reference chemical markers 
from Danshen and Gegen using developing system ethyl acetate : methanol: water = 
8 : 3 : 0.5. An indicator, 40% sulfuric acid in ethanol, was sprayed evenly onto the 
plate to visualize the bands. The TLC profile was observed under UV 254 nm before 
applying indicator and under visible light after applying indicator. 
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From the result of the TLC, the bands of 2 chemical markers, salvianolic acid B 
and puerarin, were found in the profile of the DG extract. It indicated that these 2 
chemical markers were present in the DG water extract. For tanshinone IIA, the band 
corresponding to the marker seemed to be found in the DG extract under UV 254 nm 
before applying the indicator, but it was not found when observing under visible light 
after applying the indicator. Therefore, the band appeared under UV 254 nm may be 
of a compound with a similar retention factor value as tanshinone IIA. 
3.3.2 HPLC 
HPLC was carried out by Prof. Joan Zuo's research group to detect the content 
of different markers in DG extract. A Waters HPLC system (Waters Associates, 
Milford, MA, USA) equipped with 2695 solvent delivery module and a 
996-photodiode array (PDA) UV detector was used. The chromatographic separation 
of analytes was performed under ambient temperature using an Agilent Eclipse 
XDB-C18 column (250 x 4.6 mm i.d.; 5 |Lim particle size), with the auto-sampler set 
at 4°C 土 10°C. Data were collected and analyzed by the Waters Millennium 
software (version 4.0). 
The mobile phase consisting of 0.5% acetic acid in water (solvent A) and 0.5% 
acetic acid in acetonitrile (solvent B) was run with gradient elution at a flow rate of 1 
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ml/min. The linear gradient elution was set as the following: solvent B was kept at 
5% for the first 5 minutes, and then increased to 10% in 13 minutes, then further to 
170/0, 35% and 90% in the next 12, 10 and 30 minutes, respectively, then returned to 
5% in 5 minutes and equilibrated for 15 minutes before the next injection. The 
injection volume was 50 The PDA was set for collection of spectral data from 210 
nm to 400 nm. 
Altogether 7 chemical markers were identified in the DG extract. Three of them 
were from Danshen (danshensu, protocatechuic aldehyde and salvianolic acid B) and 
four of them were from Gegen (puerarin, daidzein 8-C-apiosyl-glucoside, daidzin 
and daidzein). Figure 3.7 shows the representative HPLC chromatogram of the DG 
extract, and Table 3.2 shows the content of the various chemical markers in the 
extract. However, the tanshinone compounds were not detected in HPLC, which may 
be due to their non-polar properties and hence low solubility in aqueous extraction. 
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Figure 3.7 Representative HPLC profile of the DG extract used in the study 
detected at 280 run. (1: Danshensu; 2: Protocatechuic aldehyde; 3: Puerarin; 4: 
Daidzein 8-C-apiosyl-glucoside; 5: Daidzin; 6: Salvianolic acid B; 7: Daidzein). 
Table 3.2 Contents of different chemical markers in the DG extract. 
Compound Content (^g / 100 mg) (n = 3) 
Danshensu 1868.2 ±33.7 
Protocatechuic aldehyde 78.3 土 3.9 
Puerarin 1760.1 ±23.4 
Daidzein 8-C-apiosyl-glucoside 404.1 士 8.1 
Daidzin 159.4 ±3.3 
Salvianolic acid B 1345.7 土 18.5 
Daidzein 162.9 ± 1.4 
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3.4 Conclusion 
Based on the TLC and HPLC chemical analyses, the Danshen and Gegen raw 
herbs purchased had chemical profiles similar to that of the corresponding reference 
herbs. DG extract was confirmed to contain danshensu, protocatechuic aldehyde, 
salvianolic acid B, puerarin, daidzein 8-C-apiosyl-glucoside, daidzin and daidzein, 
but not tanshinone compounds including tanshinone IIA, due to their poor aqueous 
solubility. The powdered extract was used for further animal studies. 
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Chapter 4 Protective effect of DG extract on cerebral ischemia 
4.1 Introduction 
4.1.1 Different models of ischemia 
A wide variety of models had been used to mimic cerebral ischemia. An in vitro 
model, the oxygen-glucose deprivation (OGD) model, was commonly used 
(Goldberg & Choi, 1993; Wang et al., 2002; Chang et al., 2008; Serra-Perez et al., 
2008). During clinical ischemia, the neurons are lack of glucose and oxygen supply. 
Therefore, ischemic condition could be mimicked in vitro by removing glucose and 
oxygen in cell cultures. This model was applied on primary neuron cultures 
(Goldberg & Choi, 1993), brain slices (Seidel & Shuttleworth, 2011), as well as 
neuronal cell lines (Chang et aL, 2008). It is done by culturing the cells in a hypoxic 
chamber with glucose-free medium flushed with anaerobic gas (Serra-Perez et al.’ 
2008). Therefore, the cells are lack of glucose and oxygen. The state of reperfiision 
could be mimicked by replacing the medium with normal medium containing 
glucose, and placing the cells in a normoxic incubator. However, the OGD model 
does not completely mimic the in vivo situation. Particularly, there is the blood-brain 
barrier in the capillaries of the brain, which limit the passage of many substances. 
Some neuroprotective substances cannot cross the blood-brain barrier (Zhang & 
Pardridge, 2006; Zhang et aL, 2010) and this limitation could not be addressed in the 
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OGD model. Moreover, in clinical situations, inflammation occurs and leukocytes 
are recruited to the ischemic site. They may release proteolytic enzymes to damage 
the cells. Accumulation of leukocytes would also cause secondary blockage of the 
blood vessels. These situations are not mimicked in the in vitro model. 
Therefore, animal models of ischemia are used as they provide a better 
simulation of the actual condition in human stroke. Both global and focal ischemic 
models had been developed. Global ischemia could be induced by cardiac arrest, 
similar to the clinical setting (Eleff et al, 1991; Knapp et al., 2011), or it can be 
induced by 4-vessel occlusion (occluding both vertebral arteries and both common 
carotid arteries) (Lee et al., 2011). However, as mentioned above, global ischemia 
usually occurs during cardiac arrest. To mimic the situation in stroke patients, focal 
cerebral ischemic models would be more relevant (Wang-Fischer, 2009). 
As mentioned before, middle cerebral artery (MCA) is the most common site of 
occlusion in clinical stroke patients (O'Sullivan & Schmitz, 2007). The middle 
cerebral artery occlusion (MCAO) using an intraluminal filament is a very common 
model being used. This model could be used in rats (Zhan & Yang, 2006) and mice 
(Whitehead et al., 2011). In this method (See Chapter 2.1)，an intraluminal filament 
is inserted from the EC A into the ICA to occlude the origin of the MCA (Figure 2.4), 
which would produce infarct in the caudoputamen area of the basal ganglia (Longa et 
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al., 1989), as well as the prefrontal (Murphy et aL, 2002) and motor (Moisse et al., 
2008) cortices. MCAO could also be done by another method involving craniectomy 
(Tamura et al., 1981). As compared to this method, the intraluminal filament method 
does not need to expose the skull or the brain, thus can minimize damage caused to 
the animals. Moreover, the ischemia is reversible using the intraluminant filament 
MCAO model. Reperfusion could be achieved simply by retracting the filament from 
the vessel. This is very important as reperfusion may impose massive damage to cells. 
Another advantage is that the animals after operation are able to survive for months 
(Traystman, 2003) and the chronic effect could be studied. Although it is more time 
consuming, the MCAO model using intraluminal filament was used in the current 
study. 
Percentage brain infarction and neurological score were two common methods 
for evaluating brain damage after ischemia. Percentage of brain infarction was 
measured by staining the viable cells (Benedek et al., 2006). It was a direct 
measurement of the protection of brain cells by DG extract. As MCAO would induce 
infarction in the motor cortex (Moisse et al., 2008), hemiparesis would be resulted in 
the rats. The neurological score was a measure on the motor deficit after IR 
(Bederson et al., 1986b). 
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4.1.2 Anti-oxidative enzymes in cerebral ischemia 
Oxidative damage was one of the major routes of cellular injury in IR, 
especially during the early reperfusion period, where the anti-oxidative defense may 
be compromised (Warner et al., 2004; Yu et aL, 2008). Therefore, an induction on 
anti-oxidative enzyme might be protective towards IR. Hence, the effects of DG 
extract on the activities of three common anti-oxidative enzymes, superoxide 
dismutase (SOD), catalase and glutathione peroxidase (GPX) were evaluated. 
4.1.2.1 Superoxide dismutase (SOD) 
SOD protects the brain against oxidative damage by catalyzing the dismutation 
of the superoxide radicals into hydrogen peroxide and oxygen molecule according to 
the following equation (McCord & Fridovich, 1969): 
2O2" + 2 H + + O2 + H2O2 
There are three types of SOD with different metal ion cofactors found in human 
brains. Cu/Zn-SOD (SOD 1) presents mainly in cytosolic and lysosomal fractions, 
but is also found in the intermembrane space of mitochondria. Mn-SOD (SOD 2) is 
found in the mitochondrial matrix and the inner membrane (Okado-Matsumoto & 
Fridovich, 2001; Warner et al., 2004). Extracellular SOD (SOD 3) is also a 
Cu/Zn-SOD but is found in the extracellular space (Fridovich, 1995). All 3 isoforms 
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should be present in the brain (Freiberger et al, 2004). SOD activity up-regulation 
was suggested to be protective against brain infarct after IR in various studies (Luo et 
al., 2004; Zhan & Yang, 2006; Shukla et al., 2008). 
4.1.2.2 Catalase 
Catalase catalyzes the breakdown of hydrogen peroxide into water and oxygen 
molecule according to the following equation (Claiborne, 1985): 
2H2O2 2H2O + O2 
Catalase is a homotetramer of four ferrihemoprotein groups. It is present in almost all 
organisms and in most tissues in the body, with the highest concentration in the liver. 
It is mainly found in peroxisomes of cells (Warner et al., 2004). Catalase was 
suggested to be neuroprotective in IR in previous studies (Kuang et aL, 2006; Saleem 
et al., 2006; Zhan & Yang, 2006). 
4.1.2.3 Glutathione peroxidase (GPX) 
GPX catalyzes the reduction of hydroperoxides, including hydrogen peroxide, 
using glutathione (GSH) as a cofactor to donate electrons (Gunzler & FlohS, 1985): 
ROOH + 2GSH ROH + H2O + GSSG 
There are 4 isoforms of GPX present, all of which contain a selenocysteine group in 
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the active site (Schweizer et al., 2004). The classical GPX (GPX 1) is the first GPX 
being identified and is ubiquitously distributed in various organs of the body (Flohe 
et aL, 1973). The gastrointestinal GPX (GPX 2) is present in the gastrointestinal tract 
(Chu et aL, 1993), while the plasma GPX (GPX 3) is an extracellular enzyme present 
in the plasma (Takahashi et aL, 1987). The phospholipid hydroperoxide GPX (GPX 
4) is present in various tissues. It is especially effective in catalyzing the reduction of 
fatty acids, lipid hydroperoxides and cholesterol esters, thus preventing lipid 
peroxidation (Ursini et al., 1982). All GPX are homotetramers except GPX 4, which 
is a monomer (Brigelius-Flohe, 1999). GPX 1 and GPX 4 are present in the brain, 
and are found mainly in astrocytes and neurons, respectively (Schweizer et al., 2004). 
GPX was suggested to be protective in IR in previous studies (Luo et aL, 2004; 
Saleem et al., 2006; Zhan & Yang, 2006). 
The protective effect of DG extract on ischemia-reperfuion is evaluated in this 
Chapter. Rats were pretreated with the DG extract for 7 days before performing the 
MCAO. After 2 hours of ischemia and 24 hours of reperftision, the brain infarction 
and neurological score was determined. Moreover, the activities of anti-oxidative 
enzymes SOD, catalase and GPX were determined to detect the anti-oxidative effect 
of DG extract. 
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4.2 Materials and methods 
4.2.1 DG extract treatment, neurological deficit and brain infarction 
Male Sprague-Dawley (SD) rats weighing 190 - 195 g were obtained from the 
Laboratory Animal Services Center of The Chinese University of Hong Kong. Rats 
were housed in 1 - 2 per cage in a controlled environment with a 12-hour light / dark 
cycle. Food and water were supplied ad libitum. 
The dosage used for the rats was calculated based on the dosage used in our 
previous clinical trial (Tarn, 2004). Six capsules of DG extract were taken by each 
patient per day. Each capsule weighed 500 mg with 16 mg of excipients. Assuming a 
60 Kg human, the clinical dose used was: 
[(500 mg — 16 mg) X 6] / 60 Kg = 48.4 mg/Kg 
According to the USFDA's guideline (USFDA, 2005), the human equivalent 
dose (HED) for rat was obtained by multiplying the clinical dose by 6.2. Therefore, 
the HED was: 
48.4 mg/Kg X 6.2 = 300 mg/Kg 
Rats were randomly divided into 3 treatment groups: control (IR only), 0.3 g/Kg 
DG extract (IX HED) and 3 g/Kg DG extract (lOX HED). The IR only control group 
received distilled water as vehicle. Distilled water or DG extract was orally 
administered to the rats through an intragastric tube once daily for 7 consecutive days. 
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Dry DG extract powder was freshly dissolved in distilled water prior to use. On day 
7, one hour after receiving the final treatment, transient MCAO for 2 hours was 
carried out (See Chapter 2.1). 
After MCAO procedures, the rats were returned to cages and housed 
individually. After 24 hours reperfUsion, the neurological score of the rats were 
measured (See Chapter 2.2). The rats were then sacrificed and TTC staining was 
carried out to determine the extent of brain infarction (See Chapter 2.3). 
4.2.2 Anti-oxidative enzymes activity determination 
4.2.2.1 Treatment with DG extract and induction of cerebral ischemia 
The DG extract treatment protocol was the same as the one described above in 
Chapter 4.2.1. The rats were pretreated with 0.3 g/Kg or 3 g/Kg DG extract or 
distilled water (for the IR only group) once daily for 7 days and received 2 hour 
MCAO (See Chapter 2.1) on day 7. In addition, a sham group received the same 
MCAO operation procedure except that the suture was not inserted into the blood 
vessel. After 24 hours reperfUsion, the rats were sacrificed. The brains were dissected 
out and washed by PBS. Then, the brains were snap frozen by liquid nitrogen. They 
were then kept at - 80��un t i l enzyme extraction. 
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4.2.2.2 Extraction of enzymes from the brain 
The brain was thawed under room temperature. The right cerebrum was cut out 
and weighed. Then, it was homogenized in 0.25 g/ml ice-cold PBS using a Teflon 
homogenizer (DUALL 21, Kontes Glass Company, Vineland, NJ, USA). The 
homogenate was then centrifuged at 1,000 x g for 3 minutes and the supernatant was 
discarded. Equal volume of the cell pellet and lysis buffer, consisting of 2 mM 
magnesium chloride (Sigma-Aldrich, USA), 50 mM Tris-HCl (Sigma-Aldrich, USA), 
0.1% Trition X-100 (Sigma-Aldrich, USA), protease inhibitor cocktail tablet 
(Complete, Mini, EDTA-free Protease inhibitor cocktail tablet, Roche Diagnostics 
GmbG, Mannheim, Germany), at pH 7.4, were then added into a microcentrifuge 
tube. Freeze-thaw cycle was then carried out twice by freezing the mixtures in liquid 
nitrogen and then thawing at 3TC in a water bath. The mixture was then centrifuged 
at 10,500 X g for 10 minutes. The supernatant contained the enzymes for assay was 
separated into different aliquots and stored at -80°C until further assay. 
4.2.2.3 Determination of protein concentration 
To normalize the enzyme activity of the samples with the amount of protein, the 
protein concentration of each sample was detected. Protein concentration in the 
sample extracts was determined using the bicinchoninic acid (BCA) assay (Smith et 
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al, 1985). BCA working solution was prepared by mixing BCA solution 
(Sigma-Aldrich, USA) and copper(II) sulphate pentahydrate (CuSC^-SEbO) solution 
in 50 : 1 ratio. Protein standards were prepared by using bovine serum albumin (BSA) 
(Sigma-Aldrich, USA). 10 pL of standards (0 |Lig/ml, 2 |ig/ml, 4 |Lig/ml, 6 昭/ml, 8 
|ig/ml and 10 |ig/ml BSA) and samples were added in duplicate into different wells 
of a 96-well plate. Then, 200 \i\ of BCA working solution was added into each well 
and incubated at 37°C for 30 minutes. The absorbance at 540 nm was measured using 
a microplate reader (FLUOstar OPTIMA - Fluorescence Microplate Reader, BMG 
LAB TECH GmbH, Offenburg, Germany), with software (Fluoster Optima software 
Version 1.30-0, BMG LABTECH GmbH, Germany). The protein concentration in 
each sample was obtained from the standard curve. 
4.2.2.4 Assay kits 
SOD activity was measured by the SOD Assay Kit-WST (Dojindo Molecular 
Technologies, Inc., Rockville, MD, USA). Figure 4.1 shows the principle of the 
assay kit. A water-soluble tetrazolium salt (WST-1) was used, which would be 
changed to a water-soluble formazan dye upon reduction with a superoxide anion. 
During the assay, WST-1, xanthine oxidase (XO) and brain enzyme extracts were 
added to the wells of a 96-well plate. Superoxide was continuously generated by XO 
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while, at the same time, removed by the SOD in the sample. Any superoxide not 
removed by the SOD would reduce the WST-1 into the formazan dye. After 
incubation at 37°C for 20 minutes, the SOD activity was quantified as an inhibition 
of the formation of the formazan dye by detecting the absorbance at 450 nm using a 
microplate reader (FLUOstar OPTIMA, BMG LABTECH, Germany). 
xanthine 
O2 2O2 WST-1 formazan 
XO T 
H2O2 ^ ^ ^ ^ 202. ^ ^ ^ WST-1 
uric acid I 
SOD 
f 
O2 + H2O2 
Figure 4.1 Principle of the SOD assay kit (Dojindo Molecular Technologies, 2011) 
Catalase activity was measured by the Catalase Fluorometric Detection Kit 
(Assay Designs Inc., Ann Arbor, MI, USA). 40 |iM hydrogen peroxide solution was 
added to the brain enzyme extracts in the wells of a black 96-well plate and 
incubated at room temperature for 30 minutes. Then, a detection reagent and 
horseradish peroxidase (HRP) were added to the reaction mixture and incubated at 
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room temperature for another 15 minutes. Any H2O2 not decomposed by catalase in 
the sample would react with the non-fluorescent detection reagent and HRP to form 
the fluorescent chemical resomfin. After incubation, the concentration of resorufm 
was detected using excitation at 535 nm and emission at 595 nm by a fluorescent 
microplate reader (FLUOstar OPTIMA, BMG LABTECH, Germany). Catalase 
activity was obtained by comparing the fluorescence against a standard curve. 
GPX activity was measured by the Glutathione Peroxidase Assay Kit 
(Calbiochem, Merck KGaA, Darmstadt, Germany). Glutathione peroxidase catalyzed 
the reduction of hydroperoxides with the oxidation of glutathione (GSH). Oxidized 
glutathione (GSSG) was then reduced into GSH by glutathione reductase (GR), 
coupled with the oxidation of NADPH into NADP+, which would cause a decrease in 
absorbance at 340 nm. During the assay, brain enzyme extracts, GSH, GR and 
NADPH were added into wells of a 96-well plate. Cumene hydroperoxide was added 
as a substrate of the GPX. The plate was incubated at 25''C. As GSSG was produced 
as a result of the reducion of the cumene hydroperoxide by GPX, it was recycled into 
GSH by the GR, coupled with the oxidation of the NADPH. The activity of GPX was 
assessed indirectly by measuring the decrease in absorbance at 340 nm at one minute 
intervals for 10 minutes using a microplate reader (FLUOstar OPTIMA -
Fluorescence Microplate Reader, BMG LABTECH, Germany). 
69 
Chapter 4 Protective effect of DG extract on cerebral ischemia 
4.3 Results 
The neurological score was evaluated at 24 hours after reperfusion according to 
a scale modified from that of Bederson et al (1986b). The result is shown in Figure 
4.2. The control group received distilled water as vehicle. The neurological score of 
the control, 0.3 g/Kg and 3 g/Kg DG extract treated groups were 2.94 土 0.06, 2.82 土 
0.12 and 2.33 土 0.28, respectively. A dose-dependent decrease in neurological score 
was observed in the DG extract treated groups. The 3 g/Kg DG extract treated group 
showed a significant decrease (p < 0.05) in neurological score as compared with that 
of control. 
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Figure 4.2 Neurological score of different groups of rats after 7 days DG extract 
pretreatment. Neurological score was evaluated at 24 hours after reperfusion. Control 
group received distilled water as vehicle. Data are expressed as mean 土 SEM. n == 
11 — 18 samples. * p < 0.05 as compared with control by one-way ANOVA. 
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Rats were sacrificed after neurological scoring. The brain was harvested and cut 
into coronal slices. TTC staining was carried out to evaluate the percentage of 
infarction. The result is shown in Figure 4.3. The percentage of brain infarction in the 
control, 0.3 g/Kg and 3 g/Kg DG extract treated groups were 20.4% 土 1.7o/o, 15.3% 土 
2.7% and 12.5% 土 2.1o/o, respectively. A dose-dependent reduction in brain infarction 
was observed in the DG extract treated groups. The 3 g/Kg DG extract treated group 
showed a significant decrease (p < 0.05) in brain infarction as compared with that of 
control. 
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Figure 4.3 Percentage of brain infarction of different groups of rats after 7 days 
DG extract pretreatment. Rats were sacrificed at 24 hours after reperfusion. Control 
group received distilled water as vehicle. Data are expressed as mean 土 SEM. n = 
11 — 18 samples. * p < 0.05 as compared with control by one-way ANOVA. 
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The specific activity of SOD of the brain of different groups of rats at 24 hours 
of reperfusion is shown in Figure 4.4. The specific SOD activities of the sham, IR 
(ischemia-reperfusion), 0.3 g/Kg and 3 g/Kg DG extract treated groups were 363.5 土 
31.1 U/mg, 282.1 土 17.2 U/mg, 344.7 土 23.2 U/mg and 341.5 土 19.4 U/mg, 
respectively. The IR only group showed a significant decrease (p < 0.05) in the 
specific SOD activity as compared to the sham group. DG extract treated groups 
showed an increase in the SOD specific activities as compared to the IR only group, 
but they could not reach the level of the sham group. The activities for the 0.3 g/Kg 
and 3 g/Kg DG extract treated groups were similar and no dose-dependent effect was 
observed. 
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Specific SOD activity of the brain of different groups of rats 
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Figure 4.4 Specific SOD activity of the brain of different groups of rats at 24 hours 
of reperfusion. One unit of SOD represented the amount of enzyme that inhibited the 
reduction reaction of WST-1 with superoxide anion by 50%. Data are expressed as 
mean 土 SEM. n = 9 - 12 samples. * p < 0.05 as compared with sham by Student's 
t-test. 
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The specific activity of catalase of the brain of different groups of rats at 24 
hours of reperfusion is shown in Figure 4.5. The specific catalase activities of the 
sham, IR, 0.3 g/Kg and 3 g/Kg DG extract treated groups were 233.9 土 15.4 U/mg, 
191.5 土 9.5 U/mg, 218.6 土 23.3 U/mg and 242.8 土 14.4 U/mg, respectively. The IR 
only group showed a significant decrease (p < 0.05) in the specific catalase activity 
as compared with that of the sham group. The specific catalase activity was increased 
in a dose-dependent manner in the DG extract-treated groups, with the activity in the 
3 g/Kg treated group exceeding that of the sham group. 
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Specific catalase acitivity of the brain of different groups of rats 
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Figure 4.5 Specific catalase activity of the brain of different groups of rats at 24 
hours of reperfusion. One unit of catalase represented the amount of enzyme that 
could decompose 1.0 jimole of hydrogen peroxide per minute at 25°C. Data are 
expressed as mean 土 SEM. n = 10 - 12 samples. * p < 0.05 as compared with sham 
by Student's t-test. 
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The specific activity of GPX of the brain of different groups of rats at 24 hours 
of reperfusion is shown in Figure 4.6. The specific GPX activities of the sham, IR, 
0.3 g/Kg and 3 g/Kg DG extract treated groups were 903.7 士 27.0 U/mg, 827.9 土 
20.8 U/mg, 861.8 土 39.6 U/mg and 1033.8 土 28.4 U/mg, respectively. The specific 
GPX activity of the IR only group was significantly decreased (p < 0.05) as 
compared with the sham group. DG extract pretreatment was able to raise the level of 
specific GPX activity. A dose-dependent increase of specific GPX activity was 
shown, with a significant increase (p < 0.001) in the 3 g/Kg DG extract treated 
group. 
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Figure 4.6 Specific GPX activity of the brain of different groups of rats at 24 hours 
of reperfusion. One unit of GPX represented the amount of enzyme that could cause 
the oxidation of 1.0 nmol of NADPH to NADP+ per minute at 25°C. Data are 
expressed as mean 土 SEM. n = 10 — 12 samples. * p < 0.05 as compared with sham 
by Student's t-test. ### p < 0.001 as compared with IR only by one-way ANOVA. 
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4.4 Discussion 
4.4.1 Neurological score and percentage brain infarction 
The protective effect of DG extract on cerebral ischemia was evaluated by the 
neurological score and percentage brain infarction. Rats were pretreated for 7 days 
by DG extract or distilled water. Oral administration was chosen as the route of 
delivering the DG extract because Chinese medicine was traditionally orally taken. 
Neurological score is a measure of the neurological deficit observed after 
ischemia. As MCAO causes damage in the motor cortex on the posterior of the 
frontal lobe, paralysis of one side of the body is a common consequence (Bederson et 
al., 1986b). Conducting specific tests could consistently detect the motor deficit of 
the rats. As the occlusion was on the right hemisphere, the contralateral side (the left 
side) of the body should show abnormal motor activities. The evaluation of 
neurological score was done sequentially from the less severe deficits (lower score) 
to the more severe deficits (higher score). 
From the results (Figure 4.2), all of the rats except one in the control group 
demonstrated neurological score of 3, which means they showed contralateral 
forelimb flexion, decreased resistance to lateral push and contralateral circling when 
pulled by tail. This showed that the MCAO operation could elicit consistent 
neurological deficits. Both 0.3 g/Kg and 3 g/Kg DG extract were able to improve the 
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neurological score. This showed that DG extract was capable of relieving the motor 
dysfunction suffered after cerebral ischemia. Moreover, the protection effect was in a 
dose-dependent manner. The 3 g/Kg DG extract treated group showed a significant 
improvement in neurological deficit. Improvement in neurological deficit is much 
beneficial to stroke patients as this would mean an improvement on the disability of 
patients after stroke, which would cause a lot of inconvenience in life and need long 
term care. 
TTC is a colorless tetrazolium chemical, which could be changed to a red 
formazan upon reduction (Benedek et al., 2006). Dehydrogenases in the 
mitochondria of viable cells would reduce the TTC and so the cells would be stained 
deep red (Bederson et al., 1986a). For the dead cells, the dehydrogenase activities 
were lost and they were not stained. Thus, the living and dead cells could easily be 
distinguished. 
From the results (Figure 4.3), DG extract treated rats showed a dose-dependent 
reduction in brain infarction. 3 g/Kg DG extract treatment showed a significant 
reduction in brain infarction. The protection effect of DG extract on brain infarction 
was consistent with that of the neurological score. Therefore, preventing neuronal 
cell death may be responsible for improving the neurological deficit. In fact, both 
Danshen and Gegen were previously found to be protective against cerebral 
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infarction, through pathways including anti-oxidation (Lao et aL, 2003), 
anti-apoptosis (Xu et aL, 2005) and relieve of excitotoxicity (Sun et al., 2003). Our 
present observations correlated with those previous studies. 
4.4.2 Anti-oxidative enzyme induction 
Oxidative stress was a well documented mean of cellular damage in cerebral IR 
(Dugan & Choi, 1999; Warner et al., 2004; Chrissobolis et al., 2011). During IR, a 
large amount of ROS were produced from various sources, including mitochondria 
dysfunction and metabolism of arachidonic acid. During reperfusion, there was a 
sudden increase in oxygen and glucose supply. The mitochondria might not be able 
to utilize all and result in incomplete reduction and ROS release (Yu et al., 2008). 
The endogenous anti-oxidation enzymes, including the SOD, catalase and GPX, were 
overwhelmed by the sudden vast amount of ROS generated (Warner et al., 2004; 
Mehta et al., 2007). The enzyme proteins could be damaged and consumed by the 
ROS, resulting in a lower anti-oxidative capacity and hence more severe oxidative 
stress. A number of previous studies revealed that the restoration in anti-oxidative 
enzyme activities was linked with protecting cell death in IR (Luo et al, 2004; Zhan 
& Yang, 2006; Chen et al., 2008; Shukla et aL, 2008). In particular, Danshen and 
Gegen were shown to improve cerebral and myocardial infarction by anti-oxidative 
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pathways (Lao et aL, 2003; Wu et al, 2007). Therefore, the effect of DG extract on 
anti-oxidative enzyme induction was evaluated. 
Since the ischemia was carried out on the right hemisphere of the cerebrum, 
while the left hemisphere was intact, loss of enzyme activity might be concentrated 
on the right hemisphere. Therefore, only the right hemisphere of the cerebrum was 
used for assay in the study. This might be able to increase the difference among 
different groups. A sham group was added in the enzyme tests in order to give an 
idea on the baseline activities of the enzymes so as to provide a comparison to the IR 
group. From the results, the activities of all SOD, catalase and GPX were 
significantly lowered in the IR only group as compared with the sham group. This 
showed that the enzymes were consumed by the ROS produced during IR. However, 
DG extract was capable of inducing increase in all three kinds of enzymes. For the 3 
g/Kg DG extract treated group, the activities of catalase and GPX were even higher 
than that of the sham group. The 3 g/Kg DG extract treated group showed a 
significant increase in GPX activity as compared with the IR only group. GPX 
existed in four isoforms, in which GPX 1 and GPX 4 were found in the brain 
(Schweizer el al., 2004). Therefore, the activity detected should be due to GPX 1 and 
GPX 4. 
The functions of SOD, catalase and GPX were complementing each other 
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(Saleem et aL, 2006). SOD tackled superoxide anion, which in turn generated 
hydroxyl radicals. The hydroxyl radicals would require catalase and GPX to 
scavenge. Moreover, as GPX were capable of reducing hydroperoxides, it was 
helpful in stopping lipid peroxidation, which was a major route of cellular membrane 
damage. Therefore, the trend in increasing activities of SOD, catalase and GPX 
implied an increase in anti-oxidative defense against the range of ROS species. 
In addition to inducing anti-oxidative enzymes, in our previous studies, DG 
extract was found to be able to scavenge free radicals in AAPH-induced red blood 
cell hemolysis assay (Leung, 2003). Therefore, DG extract exerted dual effects in 
anti-oxidative defense. 
Cell death in IR was mediated through a few pathways, namely, oxidative 
damage, inflammation and apoptosis. Oxidative damage was among the early 
pathways, with inflammation and apoptosis starting a few hours after ischemia (Walz, 
1999; Huang et al., 2006). In our results, anti-oxidative enzymes were induced by 
pretreatment of DG extract. This would be beneficial in tackling the free radicals 
generated in the initial stage of ischemia as well as reperfusion. As comparing the 
results in the neurological deficit and brain infarction, the dose-dependent trend of 
increase in anti-oxidative enzymes was in line with the dose-dependent decrease in 
neurological deficit (Figure 4.2) and brain infarction (Figure 4.3). Therefore, 
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inducing anti-oxidative enzymes may be a possible way by which DG extract 
protected against neuronal death. 
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Chapter 5 Behavioral assessment using the shuttle box avoidance test on rats 
suffering from cerebral ischemia: effect of DG extract treatment 
5.1 Introduction 
5.1.1 Behavioral tests 
In the last chapter, the neurological score tested for the abnormal sensorimotor 
behavior of the rats after IR. However, it could not evaluate the higher cognitive 
functions such as learning and memory, which may be impaired for long time in 
stroke patients and affect their usual lives (Wade et al., 1986; Klein et al., 2002; Patel 
et al., 2003). To address the effect of stroke and drug treatment on learning and 
memory, different behavioral tests had been developed by scientists, including the 
radial arm maze, water maze, as well as passive and active avoidance tests. 
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Figure 5.1 The radial arm maze (modified from Crusio & Schwegler, 2005). Visual 
landmarks were added outside the maze (but visible from inside through the 
transparent walls) to help the rat locate itself. 
The radial arm maze (Figure 5.1) consists of a central circular platform with 
several arms extending from it in radial manner (Lee, 2003). The arms are lined with 
walls so that the rat cannot cross from one arm to another directly. Food is placed at 
the end of the arms and the rats need to search for it. Visual landmarks are located 
external to the maze (but visible inside the maze, e.g., signs are painted on the wall 
of the laboratory) to help the rat locate its position. The time required for the rat to 
search all the food and the number of revisiting the previously entered arms are 
recorded. This test evaluates the spatial memory of the rats. However, the rat has to 
be deprived of food for some time before the test in order to initiate its motivation to 
search for food. 
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Figure 5.2 Diagram of the water maze test (extracted from Wikipedia®, 2011). 
Visual landmarks were located outside the maze to help the rat locate itself. 
Another test for spatial memory is the water maze (DeVries et aL, 2001) (Figure 
5.2). The rat is placed in a large tank of opaque water, with an underwater platform 
with a height just below the water surface that the rat cannot see. The rat is trained to 
search for the platform so that it can stand on it and get out of the water. Again, 
visual landmarks are located outside the maze to help the rat locate itself. The time 
required for the rat to search for the platform and the distance traveled are recorded. 
Active and passive avoidance tests evaluate the ability of the animals to avoid 
an uncomfortable stimulus (usually an electric shock). For passive avoidance, the 
animals are trained to avoid the uncomfortable stimulus by suppressing certain 
behavior (DcVries el al., 2001). The passive avoidance test could be done in a 
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two-chamber box, one lighted and one dark (Kang et al., 2005). The dark chamber is 
equipped with grid floor with electric current. The rat is trained not to enter the dark 
chamber, which violates its innate behavior. The latency of entering the dark 
chamber is used as a measure for memory function. For the active avoidance test, the 
animals need to avoid the adverse stimulus by exerting certain behavior (DeVries et 
al., 2001). The active avoidance test could also be carried out in a two-chamber box. 
Electric current is given through the grid floor following a stimulus of usually light 
or sound. The rat is trained to escape to the other chamber when the stimulus is given 
in order to avoid the electric shock. The test runs in multiple cycles and the number 
of avoidances is recorded as a measure of memory function. 
Spatial memory had been associated with the hippocampus (DeVries et al., 
2001). For MCAO, although hippocampal injury had been reported (Butler et al., 
2002), it primarily affects the basal ganglia area (Yanamoto et al., 2003), which had 
been associated with the stimulus-response association (Packard & Knowlton, 2002). 
Moreover, MCAO also causes injury in the cortex, which is responsible for sensory 
input of the basal ganglia (Packard & Knowlton, 2002). Therefore, the active 
avoidance test, which involves a response generated by receiving a stimulus, was 
chosen in the present study. 
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5.1.2 Theory of the test 
The 2-way shuttle box was employed as a test for memory retaining effect of 
DG extract on cerebral ischemia (Figure 5.3). In this test, the stimuli of light and 
sound were used as signals to alert the rat to move to the other compartment of the 
shuttle box. If the rat moved to the other compartment when these signals were given, 
it could avoid an electric shock, which would otherwise be given as a punishment. 
After a series of training, the rat would acquire the memory of light and sound signal 
before the electric shock and develop the ability to avoid the shock. Memory 
retention was checked by testing the rat again in the box after cerebral ischemia and 
DG extract treatment. This model was widely used as a test for learning and memory 
(Kato et al., 2000; Stark el al., 2004; Dimitrova & Getova-Spassova, 2006; Jin et al., 
2007). 
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Figure 5.3 The shuttle box used in our study for behavioral assessment. 
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5.2 Materials and methods 
Male SD rats of 190 - 195 g were obtained from the Laboratory Animals 
Services Center of The Chinese University of Hong Kong. They were housed in 1 - 2 
per cage in a controlled environment with a 12-hour light / dark cycle. Food and 
water were supplied ad libitum. 
5.2.1 DG extract treatment 
Rats were randomly divided into 6 groups: (1) control (pretreatment only), (2) 
0.3 g/Kg DG extract (IX HED; pretreatment only), (3) 3 g/Kg DG extract (lOX HED; 
pretreatment only), (4) control (pre + post treatment), (5) 0.3 g/Kg DG extract (IX 
HED; pre + post treatment), (6) 3 g/Kg DG extract (lOX HED; pre + post treatment). 
The control groups received distilled water as vehicle. Figure 5.4 shows the 
schematic diagram of the experiment. The detailed procedures are described in the 
following sections. 
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Figure 5.4 Schematic diagram of the shuttle box experiment. 
Distilled water or DG extract was orally administered to the rats through an 
intragastric tube. Dry DG extract powder was freshly dissolved in distilled water 
prior to use. For the pretreatment groups, distilled water or DG extracts were 
administered daily for 7 consecutive days (day 1 - day 7). For the pre + post 
treatment groups, distilled water or DG extracts were administered daily for all 13 
days throughout the whole experiment. 
5.2.2 Shuttle box training and MCA O 
The 2-way shuttle box system used was an LE 916 Shuttle Box (Panlab S. L. U., 
Barcelona, Spain), consisting of two compartments of each 25 mm x 25 mm x 27 
mm size with independent grid floors and a 8 cm x 8 cm hole for passage between 
the compartments. The shuttle box was equipped with LE 900 shuttle box control 
unit and \M 100-26 shock generator, and was controlled by ShiitAvoid software 
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version 1.80 (Panlab S. L. U., Spain). 
Shuttle box training was carried out from day 4 to day 7, with one session 
(consisted of 50 trials) per rat per day. One rat was placed inside the shuttle box in 
each session. It was firstly allowed 10 minutes to explore the shuttle box. Then, 50 
trials were given, with 30 seconds of inter-trial interval after each trial. Figure 5.5 
shows the flow of each trial. 
Light + 90 ^ ^ „ • , 
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~ ^ — — • • X 50 
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Figure 5.5 Schematic diagram of each shuttle box trial. 50 trials were carried out 
in each session. 
During each trial, the conditioned stimuli of light and sound (90 dB) were 
firstly given for a maximum of 10 seconds. If the rat moved to the other 
compartment during anytime within 10 seconds, the stimuli would be stopped 
promptly. This would be counted as a conditioned response (avoidance), and the 
electric shock would not be given. If the rat did not move to the other compartment 
within 10 scconds, the unconditioned stimulus of 0.8 mA electric shock would be 
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given through the grid floor of the compartment where the rat was located for a 
maximum of 10 seconds. If the rat moved to the other compartment within these 10 
seconds, the unconditioned stimulus would be stopped promptly. This would be 
counted as an unconditioned response. If the rat did not move to the other 
compartment after 10 seconds of unconditioned stimulus, the stimulus would be 
stopped and this would be counted as a null response. The numbers of conditioned, 
unconditioned and null responses were recorded by the ShutAvoid program (Panlab 
S. L. U., Spain) automatically (Figure 5.6). 
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Figure 5.6 Shuttle box experiment in a classical active avoidance paradigm 
showing conditioned response, unconditioned response and null response. The 
shuttle box is controlled automatically by a computerized system using ShutAvoid 
program (Panlab S. L. U., 2011). 
The rats that could attain at least 60% of conditioned response, and showed at 
least 5 consccutivc conditioned responses in the last training session were considered 
Chapter 5 Shuttle box avoidance test 
successfully trained. The rats that could not attain the desired performance were 
excluded from the experiment. The successful rate of shuttle box training was about 
50% for both the pretreatment and pre + post treatment groups. On day 7, after the 
last training session, transient MCAO for 2 hours was carried out on the successfully 
trained rats (See Chapter 2.1). 
5.2.3 Shuttle box testing 
After MCAO, shuttle box testing was carried out from day 11 to day 13. One 
session was carried out for each rat per day, with procedures similar to the training 
sessions. Rats were firstly given 10 minutes to explore the shuttle box. Then, 50 
trials were carried out. The numbers of conditioned, unconditioned and null 
responses were recorded automatically. 
5.2.4 Neurological score and brain infarction 
Neurological scoring was carried out daily after the MCAO, from day 8 to day 
13. The scale used was a 4-point scale modified from that of Bederson el al (1986b) 
(See Chapter 2.2). On day 13, after the last shuttle box testing session, the rats were 
sacrificed. The brains were harvested and the percentage infarction was determined 
by TTC staining (Sec Chapter 2.3). 
% 
Chapter 5 Shuttle box avoidance test 
5.3 Results 
5.3.1 Shuttle box per formance 
The percentage of conditioned response of the pretreatment groups in the shuttle 
box is shown in Figure 5.7. The percentage of conditioned response was the 
percentage that the rat could avoid the electric shock. During the training series (day 
4 - day 7), the percentage of conditioned response in all 3 groups increased gradually. 
The performances of all the groups in the second, third and fourth training days (day 
5 — day 7) were all significantly improved as compared to that on the first day (day 4). 
The differences among the groups on individual days were not statistically 
significant. 
For the testing series (day 11 - day 13), the percentage of conditioned response 
on the first day (day 11) decreased a lot as compared with the last day of training 
(day 7), but only that of the 3 g/Kg group was significantly reduced. The 
performance of all 3 groups increased gradually to around 60% on the last day of the 
testing series. The differences between the 3 groups on individual days were not 
statistically significant. 
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Performance of different groups of rats in 2-way shuttle box (DG extract pretreatment only) 
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Figure 5.7 Percentage of conditioned response in the 2-way shuttle box for the 
pretreatment groups. Training sessions were carried out from day 4 to 7 while testing 
sessions were carried out from day 11 to 13. The data are expressed as percentage of 
conditioned response in 50 trials. Control group received distilled water only. DG 
extract or distilled water was given from day 1 to day 7. 2 hour of ischemia by 
MCAO was performed on day 7. Data are expressed as mean 土 SEM. N = 7 — 10 
samples. * p < 0.05; ** p < 0.01; *** p < 0.001 as compared to that on the first day 
of training by one-way ANOVA. # p < 0.05 as compared to that on the last day of 
training (day 7) by one-way ANOVA. 
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The percentage of conditioned response for the pre + post treatment groups in 
the shuttle box is shown in Figure 5.8. In the training series (day 4 — day 7), the 
percentage of conditioned response increased gradually for all 3 groups. Moreover, 
the increase was significant for all the groups on the second, third and fourth training 
days (day 5 — day 7) as compared to the first day (day 4). The differences among 
different groups were not statistically significant for individual days. 
For the testing series (day 11 - day 13), the percentage of conditioned response 
of all groups on the first day of testing decreased significantly as compared with the 
last day of training (day 7). The performance of all 3 groups increased gradually 
through the testing series. However, the performance of the control group on the 
second day of testing (day 12), and that of the 3 g/Kg group on the second and third 
days of testing (day 12 and day 13), were still significantly lower than that of the last 
day of training (day 7). The differences among the 3 groups on individual days were 
not statistically significant. 
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Figure 5.8 Percentage of conditioned response in the 2-way shuttle box for the pre 
+ post treatment groups. Training sessions were carried out from day 4 to 7 while 
testing sessions were carried out from day 11 to 13. The data are expressed as 
percentage of conditioned response in 50 trials. Control group received distilled 
water only. DG extract or distilled water was given from day 1 to day 13. 2 hour of 
ischemia by MCAO was performed on day 7. Data are expressed as mean 土 SEML n 
=10 samples. * p < 0.05; ** p < 0.01; *** p < 0.001 as compared to that on the first 
day of training by one-way ANOVA. # p < 0.05 as compared to that on the last day 
of training (day 7) by one-way ANOVA. 
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As comparing the pretreatment and pre + post groups (Figures 5.7 and 5.8), the 
pattern of increase of percentage conditioned response in the training series was 
similar. Although the pre + post treatment groups showed a faster learning (higher 
percentage conditioned response in second and third day of training), the 
performance on the last day of training was similar among different groups of 
pretreatment and pre + post treatment. In the testing series, both pretreatment and pre 
+ post treatment groups showed decreased percentages of conditioned response. The 
percentage conditioned response for the pre + post groups were lower than that of the 
pretreatment groups. 
However, as the performances (percentages of conditioned response) of 
different groups were different in the training series, it was not accurate to compare 
the testing performances of different groups just by using the percentage conditioned 
response. The percentage of conditioned response in the testing series was 
normalized against the percentage of conditioned response on the last day of training 
in the same group. The result of the pretreatment groups is shown in Figure 5.9. The 
performance in the testing series was expressed as the percentage of conditioned 
response as compared to the last day of training (normalized performance). The rats 
of all control, 0.3 g/Kg and 3 g/Kg groups showed an increasing trend in the testing 
series. The 3 g/Kg group showed a lower performance on the first day of testing as 
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compared to the other groups, but the decrease was not statistically significant. 
Change in percentage o f percentage conditioned response as compared to the 
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Figure 5.9 Performance of the rats in the testing series as compared to the last day 
of training for the pretreatment groups. The data are expressed as the percentage of 
conditioned response as compared to that of the last day of training. Control group 
received distilled water only. Data are expressed as mean 士 SEM. n = 7 - 10 samples. 
* 0.3 g/Kg and 3 g/Kg DG assigned groups were treated with DG extract from day 1 
to day 7 only, but not from day 8 to day 13. 
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The normalized performance for the pre + post treatment groups in the testing 
series is shown in Figure 5.10. The performance in the testing series was expressed 
as the percentage of conditioned response as compared to the last day of training. An 
increasing trend in the performance was observed in all 3 groups in the testing series. 
The 3 g/Kg group showed a lower performance on the testing series, but the 
difference was not statistically significant. 
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Change in percentage o f avoidance as compared to last day o f training 
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Figure 5.10 Performance of the rats in the testing series as compared to the last day 
of training for the pre + post treatment groups. The data are expressed as the 
percentage of conditioned response as compared to that of the last day of training. 
Control group received distilled water only. Data are expressed as mean 土 SEM. n = 
10 samples. 
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As comparing the performance of the pretreatment and pre + post treatment 
groups in the testing series (Figures 5.9 and 5.10), both pretreatment and pre + post 
treatment groups showed increase in performance along the testing series. However, 
the performance of the pre + post treatment groups was lower than that of the 
pretreatment groups. The percentages of conditioned response as compared to the last 
day of training for the pre + post treatment groups were around 10% lower than that 
of the corresponding pretreatment groups. 
5.3.2 Neurological score 
The neurological score was evaluated daily from day 8 to day 13 using the same 
scale modified from that of Bederson et al. (1986b), as mentioned in Chapter 4. The 
result of the pretreatment groups is shown in Figure 5.11. The 3 g/Kg DG extract 
treated group showed a decreasing trend on the neurological score. Moreover, the 3 
g/Kg DG extract treated group showed a lower neurological score than the control 
and 0.3 g/Kg DG extract treated groups from day 9 to day 13, but the difference 
among the groups on individual days were not statistically significant. As comparing 
the percentage change of neurological score of individual rats, the average 
percentage decrease of neurological score on day 13 as compared to that on day 8 
was 13.3% 土 7.40/0 and 23.8% 土 15.8o/o for the control and 3 g/Kg DG extract treated 
105 
Chapter 5 Shuttle box avoidance test 
groups, respectively. However, the neurological score of the 0.3 g/Kg DG extract 
treated group was increased by 16.7% 土 20.4%. 
Neurological score of rats in shuttle box experiment 
(DG extract pretreatment only) 
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Figure 5.11 Neurological score of shuttle box rats of pretreatment groups after 
MCAO. Control group received distilled water only. DG extract or distilled water 
was given from day 1 to day 7, and 2 hour MCAO was performed on day 7. Data are 
expressed as mean 土 SEM. n = 7 — 10 samples. 
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The neurological score of pre + post treatment groups is shown in Figure 5.12. 
The control, 0.3 g/Kg and 3 g/Kg DG extract treated groups showed decreasing 
trends of neurological score along time. The decreases in the DG extract treated 
groups were larger than that of the control group. The 0.3 g/Kg DG extract treated 
group showed the lowest score among the groups on all days. The differences among 
groups were not statistically significant on individual days. As comparing the 
percentage change of neurological score of individual rats, the average percentage 
decrease of neurological score on day 13 as compared to day 8 was 10.0% 土 7.1o/o, 
25.0% 土 13.90/0 and 28.3% 士 8.6% for the control, 0.3 g/Kg and 3 g/Kg DG extract 
treated groups, respectively. 
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Neurological score of rats in shuttle box experiment 
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Figure 5.12 Neurological score of shuttle box rats of pre + post treatment groups 
after MCAO. Control group received distilled water only. DG extract or distilled 
water was given from day 1 to day 13, and 2 hour MCAO was performed on day 7. 
Data are expressed as mean 土 SEM. n 二 10 samples. 
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As comparing the neurological score of the pretreatment and pre + post 
treatment groups (Figures 5.11 and 5.12), the initial neurological scores of both 
pretreatment and pre + post treatment groups at day 8 lied within the range of 2.3 — 
2.9. The 0.3 g/Kg and 3 g/Kg pre + post treatment groups showed a larger decrease 
in neurological score along the time as compared to the corresponding pretreatment 
groups. 
5.3.3 Brain infarction 
At day 13, rats were sacrificed after the last testing session. The brains were 
taken out, sliced and stained by TTC to detect the percentage infarction. The result of 
the pretreatment groups is shown in Figure 5.13. The percentage brain infarction in 
the control, 0.3 g/Kg and 3 g/Kg DG extract pretreatment groups were 10.0% 土 1.8°/o, 
9.9% 士 1.7o/o and 11.3% 土 2.1o/o, respectively. There was a slight increase in the 
percentage brain infarct in the 3 g/Kg group, but the difference among different 
treatment groups was not statistically significant. 
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Brain infarction of rats in different groups of shuttle box test 
(DG extract pretreatment only) 
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Figure 5.13 Percentage brain infarction of pretreatment groups of rats of shuttle 
box test at last day of testing (day 13). Control group received distilled water only. 
DG extract or distilled water was given from day 1 to day 7. 2 hour MCAO was 
performed on day 7. Data are expressed as mean 土 SEM. n = 7 — 10 samples. 
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The percentage brain infarction for the pre + post treatment groups is shown in 
Figure 5.14. The percentage brain infarct of control, 0.3 g/Kg and 3 g/Kg pre + post 
treatment groups were 12.1% 土 1.5o/o, 11.8% 土 2.0o/o and 9.6% 土 2.6o/o, respectively. 
The 3 g/Kg DG extract treated group showed a decrease in percentage brain infarct, 
but the difference was not statistically significant. 
Brain infarction of rats in different groups of shuttle box test 
(DG extract pre+post treatment) 
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Figure 5.14 Percentage brain infarction of pre + post treatment groups of rats of 
shuttle box test at last day of testing (day 13). DG extract or distilled water was given 
from day 1 to day 13. 2 hour MCAO was performed on day 7. Data are expressed as 
mean 土 SEM. n = 10 samples. 
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As comparing the pretreatment and pre + post treatment groups (Figures 5.13 
and 5.14), the control and 0.3 g/Kg pre + post treatment groups showed a slightly 
larger percentage brain infarct as compared to the corresponding pretreatment groups, 
while the 3 g/Kg pre + post treatment group showed a lower percentage brain infarct 
as compared to the corresponding pretreatment group. Moreover, the 3 g/Kg 
pretreatment group showed a larger infarct as compared with that of the 0.3 g/Kg 
pretreatment group, while the 3 g/Kg pre + post treatment group showed a smaller 
infarct as compared to the 0.3 g/Kg pre + post treatment groups. 
5.4 Discussion 
5.4.1 The shuttle box protocol 
The shuttle box active avoidance test was a memory test of the rats on response 
to stimulus. The conditioned stimulus was the stimulus used to trigger a behavior of 
the rat that is not normally associated with the stimulus (DeVries et aL, 2001), which 
in this case is the movement to another chamber. Otherwise, a punishment 
(unconditioned stimulus) (DeVries et al., 2001), which in this case is an electric 
shock, would be given to the animals to force them to exhibit the desired behavior. In 
the test, the rats were firstly trained to acquire the ability to move to the other 
chamber when the conditioned stimuli were given. Then, memory retention effect of 
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the DG extract was tested after MCAO surgery. 
In the training sessions, 3 - 5 days of training were reported in previous studies 
(Kato et al., 2000; Dimitrova & Getova-Spassova, 2006; Zhang et al., 2006a) for 
successful training. From the preliminary test, 4 days of training was chosen. To 
comply with the protocol in the previous tests, 7 day DG extract pretreatment was 
given to the rats. Therefore, training started on day 4 and ran till day 7. In each 
session, 50 trials were given to the rats (Veerendra Kumar & Gupta, 2002). The 
conditioned stimuli were light and sound (90 dB), following previous reports (Kato 
et aL, 2000). The unconditioned stimulus was an electric shock of 0.8 mA (Kato et 
al., 2000). Electric shock was used as the unconditioned stimulus in almost all shuttle 
box tests (Kato et al., 2000; Van der Borght et al, 2005; Dimitrova & 
Getova-Spassova, 2006; Zhang et al., 2006a). In the last training session, animals 
showing 60% avoidance and 5 consecutive avoidances (Van der Borght et al., 2005; 
Chan, 2008) were considered successfully trained, and MCAO was carried out on 
them. The rats that could not be trained were excluded from the test. After MCAO, 3 
days were given to the rats for them to recover from the injury, and the testing 
sessions began afterwards on day 11. It was found that the training successful rate 
was rather low (about 50%). The successful rate was similar among different 
treatment groups. This learning ability might be due to individual differences. 
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5.4.2 Shuttle box per formance 
5.4.2.1 Pretreatment groups 
During the training sessions, the percentage of conditioned response in the 
pretreatment groups increased gradually, as expected. Significant improvement was 
seen starting from the second day of training. Some of the rats started to attain the 
required level of 60% conditioned response on the third day. However, to comply 
with the protocol, these rats were still given the fourth training session. 
For the testing sessions, the performance of all groups decreased a lot on the 
first day (day 11), as expected, as IR should be damaging the neuronal cells in the 
basal ganglia region responsible for memory (Packard & Knowlton, 2002), 
especially for stimulus-response associations. Moreover, the motor cortex was also 
damaged, which led to deficits in movement of the rats (Figure 5.14). 
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Figure 5.15 The brain slice, 8 mm from the frontal pole, showing the dilTerent 
areas damaged by MCAO. 
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The performance increased gradually again through the testing series. This 
showed that memory was being built up again, but the increase was much slower 
than that in the training series. There was no significant increase observed. This may 
probably be due to damage in the brain by IR. 
The DG extract pretreatment groups did not show an increase in shuttle box 
conditioned response as compared with that of control. The rats were not fed with 
DG extract after ischemia. Although the pretreated DG extract might act on the 
anti-oxidation pathway within few hours after ischemia (as shown in Chapter 4), they 
might not have been protected brain cells from delayed cell damaging mechanisms 
like inflammation and apoptosis, which starts a few hours after ischemia initiation 
and continued even after days (Walz, 1999; Mehta et al., 2007). 
5.4.2.2 Pre + post treatment groups 
For the pre + post treatment groups, in the 4-day training session, the percentage 
of conditioned response increased gradually. Significant improvement was seen 
starting from the second day of training. Some of the rats attained the required level 
of 60% conditioned response on the third day. However, to comply with the protocol, 
these rats were still given the fourth training session. 
During the first testing session (day 11), the performance of all 3 groups were 
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significantly lower than that of the last day of training (day 7), which might be due to 
damage of brain neurons responsible for memory. The performance increased 
gradually through the 3 days of testing, but again the increase was much slower than 
that in the training sessions, and some of the groups still showed a significantly lower 
performance on testing days 2 and 3, as compared to the last day of training. In 
addition, the 3 g/Kg group showed consistent low performances. This finding was 
interesting and might need further investigation, as the 3 g/Kg group displayed 
protective effect on the brain infarction as well as the neurological score. It might be 
possible that the grabbing of the rat and its struggling during drug feeding, or 
indigestion as seen in some of the rats, made the rat feeling uncomfortable and 
lowered its initiative to move. 
5.4.2.3 Comparison ofpretreatment and pre + post treatment groups 
As comparing the pretreatment and pre + post treatment groups, in the training 
sessions, similar increasing patterns were observed. The rats of all the pretreatment 
and pre + post treatment groups reached the performance of about 80% conditioned 
response on the last day of training (day 7). There was no significant difference 
among the performance of rats in control, 0.3 g/Kg and 3 g/Kg DG extract treated 
groups for both pretreatment and pre + post treatment. This showed that the DG 
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extract did not show an observable effect on learning, and the rat can acquire the 
ability to avoid the electric shock naturally. 
In the testing series, the percentage of conditioned response of the pre + post 
groups was lower than the corresponding pretreatment groups. However, after 
normalization, there was no significant difference in the performance among 
different groups in both pretreatment and pre + post treatment. Hence, the difference 
in performance may be due to individual and inter-experimental variations. 
5.4.3 Ne urological score 
For the pretreatment groups, the 3 g/Kg group showed a lower score as 
compared to the control and 0.3 g/Kg group. It also showed a slightly decreasing 
trend. However, there was no significant difference among the DG extract treated 
groups and control group on all days. No effect of the DG extract pretreatment on 
neurological score was observed. 
For the pre + post treatment groups, a decreasing tendency in neurological score 
was seen in all 3 groups throughout the 6 days after MCAO. The difference among 
the DG extract treated groups and control were not statistically significant. However, 
there was a trend that DG extract treated groups showed lower neurological scores. 
After calculating the percentage decrease in neurological score, it was found that the 
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improvement in neurological score was dose-dependent. Therefore, DG pre + post 
treatment might have an effect in improving the neurological deficit after cerebral 
ischemia. 
5.4.4 Brain infarction 
For the percentage brain infarction, there was no significant difference among 
the different pretreatment groups. Yet, the 3 g/Kg pretreatment group showed a 
slightly larger infarction. No effect of the DG extract was observed on percentage 
brain infarction. This also correlated with the results of the shuttle box and 
neurological score tests. 
For the pre + post treatment groups, the 3 g/Kg group showed a decreased 
percentage infarction. This observation correlated with that of the neurological score 
test, and might provide an explanation for it. However, the decrease was not 
statistically significant. 
As comparing the pretreatment and pre + post treatment groups, infarction of 
control and 0.3 g/Kg pre + post treatment groups were slightly larger than that of the 
corresponding pretreatment groups. This might be due to inter-experimental 
variations. However, the 3 g/Kg pretreatment group showed a larger infarct than the 
other pretreatment groups, but was reduced in the pre + post treatment group. This 
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might prove that 3 g/Kg pre + post treatment had some protective effect on IR. 
At the stage of reperfusion and later, free radicals were continued to be released 
(Walz, 1999). As the anti-oxidative defense system might have been disrupted during 
the ischemic period (Warner et aL, 2004; Yu et al., 2008), the neurons might be even 
more vulnerable to oxidative damage in the later stages. DG extract was able to 
protect brain cells through anti-oxidative pathways, as shown in Chapter 4. Moreover, 
neuronal cells could also be damaged through the later pathways of inflammation 
and apoptosis. 3 g/Kg DG extract pre + post treatment might also protected the cells 
through these pathways in addition to anti-oxidation, and hence resulted in a lower 
brain infarct. For the 0.3 g/Kg DG extract pre + post treatment group, the effect 
might not be strong enough to protect the cells. 
5.4.5 Conclusion 
In summary, it was found that pre + post treatment of DG extract showed a 
slight reduction in neurological deficit and brain infarction induced by IR, while no 
effect on stimulus-response association memory was shown using the shuttle box 
avoidance test. However, DG extract pretreatment did not exhibit protective effect on 
brain cells, neurological deficit or memory retention, probably due to discontinued 
intervention of DG extract treatment after MCAO. DG extract pre + post treatment 
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was shown to have better effects than pretreatment alone, probably due to the 
continued intervention of DG extract treatment on the later pathways (inflammation 
and apoptosis). 
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6.1 Introduction 
During IR, the endothelium of the blood vessels would be damaged by various 
mechanisms such as free radical attack (Dugan & Choi, 1999) and inflammation 
(Justicia et al., 2003). The damage would activate hemostatic mechanisms to form 
blood clots to stop bleeding from the injured site. The mechanisms are generally 
divided into primary hemostasis and secondary hemostasis (Kamal et al., 2007). 
Primary hemostasis involves the activation and aggregation of platelets. 
Platelets are bound to collagen in the subendothelium at the damage site by the 
glycoprotein (GP) Ib/V/IX receptor complex via the von Willebrand factor (vWF), as 
well as by the GP VI receptor directly. This would trigger the release of ADP and 
thromboxane A2 from the platelets, which stimulate recruitment of more platelets. 
The platelets are held together by fibrinogen or vWF to form a platelet plug, which 
covers the damaged site of the endothelium to stop bleeding (Davie et aL, 1991; 
Varga-Szabo et al., 2008; Angiolillo et al., 2010). 
Secondary hemostasis involves the blood coagulation cascade, which forms a 
fibrin clot to strengthen the platelet plug. The blood coagulation cascade is shown in 
Figure 6.1. It involves a number of serine proteases, called coagulation factors, 
which circulate in the form of zymogen in blood, and are activated in sequence when 
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endothelium damage occurs. The coagulation cascade could be triggered by the 
extrinsic or intrinsic pathway, which finally leads to a common pathway and 
formation of a cross-linked fibrin clot. 
Intrinsic Pathway 
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Figure 6.1 The blood coagulation cascade (modified from McGilvray & Rotstein, 
2001). The cascade can be triggered by the extrinsic or intrinsic pathway, which both 
leads to the final common pathway and formation of cross-linked fibrin clot. 
When endothelium damage occurs, the cascade is firstly triggered by the 
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extrinsic pathway. Factor VII is a circulating zymogen while tissue factor is located 
in the adventitia area outside the endothelium. When vessel damage happens, Factor 
VII and tissue factor come into contact and form a complex. This triggers the 
activation of other coagulation factors and finally forms the cross-linked fibrin. The 
cross-linked fibrin produces an insoluble clot, which stabilizes and consolidates the 
platelet plug (Davie et al., 1991; Dahlback, 2000). The intrinsic pathway is another 
pathway to initiate the coagulation cascade. It is triggered when Factor XI is 
activated by the thrombin generated through the extrinsic pathway, or when Factor 
XII is activated by kallikrein (Davie et al., 1991; Gailani & Renne, 2007; Muller et 
al., 2009). 
When endothelium is damaged during ischemia, the above mentioned 
hemostasis pathwasys are triggered. However, the blood clots would cause further 
blockage in the blood vessel. This often happens in the capillaries and results in 
microvascular thrombi (Xu et al., 2010). During the reperfusion period, vast amount 
of oxygen free radicals are released (Dugan & Choi, 1999) and vessels are damaged 
by them. The coagulation thus initiated would cause the ‘no-reflow phenomenon' 
(Ames el al., 1968) after reperfusion, which accounts for a hypoperfusion period in 
the original ischemic territory after reperfusion of the occluded vessel. Moreover, 
secondary ischemia could be resulted and it would impose further damage to the 
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neuronal cells (Bottiger & Martin, 2001; Wang et aL, 2008). Coagulation could also 
trigger inflammatory effects such as leukocyte migration (Jennewein et al., 2011), 
which would cause further damage to the ischemic cells. From previous studies, it 
was suggested that anti-coagulation drugs like heparin was able to protect brain cells 
from cerebral ischemia (Quartermain et al., 2003; Xu et al., 2010), and various 
anti-platelet agents were able to prevent stroke recurrence (Bednar & Gross, 1999). 
Blood coagulation is commonly measured by tests including bleeding time, 
activated partial thromboplastin time, prothrombin time, thrombin time, and platelet 
aggregation (Dahlback, 2000). Prothrombin time and activated partial thromboplastin 
time are measures of the extrinsic and intrinsic pathways of coagulation, respectively 
(Kamal et al., 2007). In prothrombin time, the thromboplastin reagent containing 
tissue factor, phospholipids and calcium ions are added to plasma to trigger the 
extrinsic pathway, and the time required to form a clot is measured. In activated 
partial thromboplastin time, the partial thromboplastin reagent, which is lack of 
tissue factor, is added to trigger the intrinsic pathway of coagulation. For the 
thrombin time, the coagulation is initiated by adding thrombin (Flanders et al., 2003). 
It is specific to determine abnormalities in fibrinogen, or the effect of thrombin 
inhibitors such as heparin. 
In the present study, a tail bleeding test was used to determine the effect of DG 
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extract on blood coagulation (Makino et al., 2002). The tail bleeding time, number of 
rebleedings and blood loss were evaluated. As the extrinsic pathway is the major 
route of activating the blood coagulation cascade in endothelial disruption (Davie et 
al., 1991; Dahlback, 2000), the effect of DG extract on prothrombin time was 
evaluated. To address the effect on primary hemostasis, the anti-platelet aggregation 
effect of DG extract was also measured. Warfarin, a widely used oral anti-coagulant 
drug, was used as the positive control for comparing the anti-coagulation effect with 
DG extract. 
6.2 Materials and methods 
6.2.1 Treatment with DG extract and warfarin 
Male SD rats weighing 295 - 305 g were obtained from the Laboratory Animals 
Service Center of The Chinese University of Hong Kong. They were housed in 3 per 
cage in a controlled environment with a 12-hour light / dark cycle. Food and water 
were supplied ad libitum. 
Rats were randomly divided into 4 treatment groups: negative control (distilled 
water), 0.3 g/Kg DG extract (IX HED), 3 g/Kg DG extract (lOX HED) and positive 
control (0.25 mg/Kg warfarin). Distilled water, DG extract or warfarin was orally 
administered to the rats through an intragastric tube once daily for 5 consecutive days. 
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Dry DG extract and warfarin powder were freshly dissolved in distilled water prior to 
use. On day 5, after receiving the final treatment for one hour, the following 
procedures were carried out. 
6.2 2 Tail bleeding time and volume 
The rat was firstly anesthetized by intraperitoneal injection of a mixture of 
ketamine (75 mg/Kg) and xylazine (10 mg/Kg). 10 ml of 0.9% saline (w/v) was 
placed in a plastic test tube in a water bath at 37°C. The rat was then wrapped with a 
towel and a precise transection was made at 2 mm from the tip of the tail. The rat 
was placed next to the water bath and 3 cm of the distal portion of the tail was 
immersed in the plastic test tube with saline. Bleeding from the tail transection was 
timed and the number of rebleedings was recorded. Rebleeding was defined as 
bleeding again within 30 seconds after previous bleeding had stopped. The bleeding 
test was monitored for 30 minutes. 
The blood collected in the test tube was then centrifuged at 200 x g for 10 
minutes to separate the red blood cells. The supernatant was removed and the red 
blood cells were lysed by 10 ml distilled water. The red blood cell concentration was 
detected by measuring the absorbance of 200 [i\ of the red blood cell lysate at 405 
nm using a microplate reader. 
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6.2.3 Prothrombin time 
After the bleeding test, blood was collected from the inferior vena cava of the 
rats with 3.2% sodium citrate solution as anti-coagulant. The blood and sodium 
citrate was in a ratio of 1:9 (v/v) (Final concentration of sodium citrate was 0.32%). 
The blood was divided into two portions for the prothrombin time and platelet 
aggregation tests. The first portion of the blood was centriftiged at 2000 x g for 10 
minutes and the plasma was collected for assay. The thromboplastin reagent (Helena 
Laboratories, Inc., Beaumont, TX, USA) contained tissue factor, calcium ions and 
phospholipids. The thromboplastin reagent and plasma were pre-warmed at 37°C. 0.2 
ml of the thromboplastin reagent was added to 0.1 ml of the plasma in a 
microcentrifuge tube. The mixture was stirred gently using a pipette tip and the time 
for a clot to be formed was recorded as the prothrombin time. 
6.2.4 Platelet as^sresation 
The second portion of the citrated blood collected was centrifuged at 200 x g for 
20 minutes. The supernatant was collected into a 15 ml centrifuge tube and used as 
the platelet-rich plasma (PRP) in the experiment. The aggregometer (Model 500, 
Chrono-log, Havertown, PA, USA) was warmed up for 40 minutes before the 
experiment. 500 |il of Krcbs solution (containing 118 mM NaCl, 4.7 mM KCl, 0.57 
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mM MgS04, 2.5 mM CaCli, 1.2 mM KH2PO4, 25 mM NaHCOs and 11.8 mM 
glucose) was added into a cuvette with stir bar and used as the reference of the 
aggregometer. For the samples, 230 \il Krebs solution and 250 \il of PRP were added 
to a cuvette with stir bar. The aggregation was measured as the baseline value. Then, 
20 \i\ of collagen (final concentration 6 |^g/ml) was added to initiate the aggregation. 
The aggregation was measured for further 6 minutes. 
6.3 Results 
The tail bleeding test was done on day 5 at one hour after the final treatment. 
The tail bleeding time was recorded for a maximum period of 30 minutes. Bleeding 
was considered as stopped when no rebleeding was observed for 30 seconds. The 
result is shown in Figure 6.2. The average bleeding time for the control, 0.3 g/Kg DG 
extract, 3 g/Kg DG extract and warfarin groups were 5.7 土 0.6 minutes, 7.8 土 0.5 
minutes, 17.8 土 2.6 minutes and 29.3 土 0.7 minutes, respectively. The warfarin group 
showed the longest bleeding time, and it was significantly longer as compared with 
that of the control (p < 0.0001). There was a dose-dependent increase in the bleeding 
time for the DG extract treated groups. The 3 g/Kg DG extract treated group showed 
a significant increase in the tail bleeding time as compared with that of control (p < 
0.001) as well as the 0.3 g/Kg DG extract treated group (p < 0.01). 
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Figure 6.2 Tail bleeding time of different groups of rats. Tail bleeding was 
measured for a maximum period of 30 minutes. Bleeding was considered as stopped 
when no rebleeding was observed in 30 seconds. Data are expressed as mean 土 SEM. 
n = 6 samples. *** p < 0.001 as compared with control by one-way ANOVA. ^^ p < 
0.01 as compared to 0.3 g/Kg DG extract treated group by one-way ANOVA. #### p 
< 0.0001 as compared to control by Student's t-test. 
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Rebleeding was counted when bleeding started again within 30 seconds after it 
previously stopped. The result is shown in Figure 6.3. The average number of 
rebleeding in the control, 0.3 g/Kg DG extract and 3 g/Kg DG extract groups were 
1.2 土 0.4 times, 1.8 土 0.3 times and 4.5 土 1.3 times, respectively. For the warfarin 
group, since bleeding was continuous within the measuring period, no rebleeding 
was noted. For the DG extract treated groups, there was a dose-dependent increase in 
the number of rebleedings as compared with that of the control, and the 3 g/Kg DG 
extract treated group showed a significant increase (p < 0.05) in the number of 
rebleedings as compared with that of control. 
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Figure 6.3 Number of rebleedings in different groups of rats in the tail bleeding 
test. Rebleeding was counted when bleeding started again within 30 seconds after it 
stopped previously. Bleeding was continuous in the warfarin group and so no 
rebleeding was counted. Data are expressed as mean 土 SEM. n = 6 samples. * p < 
0.05 as compared with that of the control by one-way ANOVA. 
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The volume of blood loss in the bleeding test was determined by a simple 
colorimetric method. The result is shown in Figure 6.4. The blood loss was expressed 
as percentage of the control group. The blood loss of the 0.3 g/Kg DG extract, 3 g/Kg 
DG extract and warfarin groups were 130.3% 土 3.9o/o, 280.3% 士 51.2o/o and 2845.0% 
土 618.2% of that of the control, respectively. The warfarin group showed a 
significant increase (p < 0.01) in blood loss as compared with that of the control. The 
DG extract treated groups showed a dose-dependent increase in blood loss, and a 
significant increase was observed in the 3 g/Kg DG extract treated group as 
compared with that of control (p < 0.01) as well as the 0.3 g/Kg DG extract treated 
group (p< 0.01). 
132 
Chapter 6 Anti-blood coagulation effect of DG extract 




2000 ^ — — 
0 1000 ^ — — 
H a> o 
B 4001 ^ — — 
1 ； 
二 300 ^ 
II • 
200 ^ —— 
:MzidbH 
/ / 冬》々  
CP o午 o十 
Figure 6.4 Blood loss of different groups of rats during the tail bleeding test. The 
data are expressed in percentage of the control group, and as mean 士 SEM. n = 6 
samples. ** p < 0.01 as compared with control by one-way ANOVA. ^^ p < 0.01 as 
compared with the 0.3 g/Kg DG extract treated group by one-way ANOVA. ## p < 
0.01 as compared with that of the control by Student's t-test. 
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The prothrombin time of the plasma of different groups of rats is shown in 
Figure 6.5. The prothrombin times of different groups are expressed as the ratio as 
compared with that of control. The prothrombin time ratio of the 0.3 g/Kg DG 
extract, 3 g/Kg DG extract and warfarin groups were 1.04 土 0.01, 1.13 土 0.03 and 
1.56 土 0.16, respectively. The warfarin group showed the longest prothrombin time 
among different groups and was significantly longer (p < 0.01) as compared with that 
of control. The DG extract treated groups showed a dose-dependent increase in the 
prothrombin time as compared with that of control. The 3 g/Kg DG extract treated 
group showed a significant increase in prothrombin time as compared with that of the 
control (p < 0.001) and the 0.3 g/Kg DG extract treated group (p < 0.01). 
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Figure 6.5 Prothrombin time of the plasma of different groups of rats. The 
prothrombin times are expressed as ratios of the control group, and as mean 土 SEM. 
n 6 samples. *** p < 0.001 as compared with control by one-way ANOVA. aa p < 
0.01 as compared with the 0.3 g/Kg DG extract treated group by one-way ANOVA. 
## p < 0.01 as compared with that of the control by Student's t-test. 
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The effects of DG extract and warfarin on platelet aggregation were evaluated 
as the percentage inhibition of platelet aggregation as compared to that of the normal 
rats. The results are shown in Figure 6.6. The percentage inhibition of platelet 
aggregation for the control, 0.3 g/Kg DG extract, 3 g/Kg DG extract and warfarin 
groups were 1.6% 土 1.5o/o, 4.9% 土 1.8o/o, 88.0% 土 l . m and 95.6% 土 1.9o/o, 
respectively. The warfarin group showed the greatest inhibition effect on platelet 
aggregation and was significantly increased (p < 0.0001) as compared with that of 
control. The DG extract treated groups showed a dose-dependent effect on inhibition 
of platelet aggregation. The 3 g/Kg group showed a significant increase on platelet 
aggregation inhibition as compared with that of control (p < 0.001) and the 0.3 g/Kg 
DG extract treated group (p < 0.001). 
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Figure 6.6 Percentage inhibition of platelet aggregation in different groups of rats. 
Data are expressed as mean 土 SEM. n = 4 samples. *** p < 0.001 as compared with 
control by one-way ANOVA.八八八 p < 0.001 as compared with that of the 0.3 g/Kg 
DG extract treated group by one-way ANOVA.冊冊 p < 0.0001 as compared with 
control by Student's t-test. 
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6.4 Discussion 
The anti-blood coagulation effect of DG extract was evaluated using the tail 
bleeding test, prothrombin time test and platelet aggregation test. Warfarin, a 
commonly used oral anti-coagulant (Paciaroni & Bogousslavsky, 2010), was used as 
a positive control to compare the effect with that of the DG extract. 
The bleeding test was a direct measurement on blood clotting effect of DG 
extract on a wound. The terminal portion of the tail of the SD rat was transected and 
the tail bleeding was observed. Warfarin showed the strongest effect in prolongation 
of the tail bleeding time (Figure 6.2) and caused the largest amount of blood loss 
(Figure 6.4). It also caused a continuous bleeding throughout the experiment (Figure 
6.3). Although not as strong as warfarin, DG extract showed a dose-dependent 
increase in the tail bleeding time, number of rebleedings and blood loss. This showed 
that DG extract was capable of inhibiting blood coagulation. Therefore, DG extract 
might be useful in preventing the microvascular thrombosis during IR in stroke, as 
well as secondary ischemia. Moreover, 3 g/Kg DG extract showed a significantly 
longer tail bleeding time and significantly more blood loss than 0.3 g/Kg DG extract, 
which suggested that the 3 g/Kg DG extract was more effective. However, it is 
important that DG extract would not cause non-stop bleeding as compared with 
warfarin as it is a life-threatening aspect of patients with vascular problems who take 
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warfarin as an anti-coagulant. 
The prothrombin time was a measurement on the extrinsic pathway of 
coagulation (Figure 6.1), which was the major pathway for the initiation of 
coagulation (Davie et al., 1991). It was a classical clinical test for the deficiency of 
Factors VII, X and prothrombin, which were involved in the extrinsic pathway 
(Ansell et aL, 2004). Thromboplastin was added to trigger the extrinsic pathway in 
the test. As correlated with the tail bleeding test, warfarin showed the strongest effect 
on prothrombin time prolongation, while DG extract showed a milder, 
dose-dependent prolongation. This showed that DG extract exhibited its effect of 
anti-blood coagulation through inhibiting the extrinsic pathway. As the extrinsic 
pathway was involved in initiation of coagulation, it might suggest that DG extract 
was able to prevent the initiation of formation of thrombi. In clinical setting, 
prothrombin time is measured as international normalized ratio (INR) for 
standardization in order to cope with the variations in thromboplastin reagents 
provided by different manufacturer and also among different batches (Le et al., 1994). 
However, we used the same batch of reagent to measure the prothrombin time 
throughout the experiment and therefore we used prothrombin time ratio instead. 
Platelet aggregation was another major pathway of blood coagulation. Platelet 
aggregation was previously shown to increase after MCAO (Terao et al,, 2008). In 
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our results, warfarin showed the best effect in inhibiting platelet aggregation among 
all groups. The inhibition effect of DG extract on platelet aggregation was once again 
dose-dependent, suggesting that DG extract also exerted the anti-coagulation effect 
through inhibition of platelet aggregation. In fact, Danshen was previously shown to 
have anti-platelet effects (Wang et al., 1994; Jin et al., 2000). Therefore, the 
anti-platelet effect of DG extract should be, as least partly, due to Danshen. 
Anti-coagulants and anti-platelet drugs were shown to protect cells from 
ischemia (Bednar & Gross, 1999; Xu et al., 2010). It was suggested to give 
anti-coagulants to patients with atrial fibrillation or high blood pressure to prevent 
ischemia (Jorgensen et al., 1997; Sherman et al., 2005). As 3 g/Kg DG extract 
pretreatment possessed strong anti-coagulation and anti-platelet aggregation effect，it 
might be able to prevent microthrombi formation and recurrence of ischemia. 
As comparing the results of DG extract and warfarin, the anti-coagulation effect 
of warfarin was much stronger than DG extract. However, warfarin might cause 
uncontrolled bleeding, as shown in the tail bleeding test. In fact, hemorrhage was a 
high risk to patients undertaking warfarin and need to be monitored by prothrombin 
time regularly (Dahlback, 2000). DG extract showed a milder effect on anti-blood 
coagulation, but the risk of hemorrhage would be smaller. Hence, it might show a 
more balanced effect between anti-coagulation and the risk of uncontrolled bleeding. 
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7.1 General discussion and conclusion 
Cerebral ischemia is a serious problem all over the world and its prevalence 
keep on growing and introduces huge burdens on the family and societies. It involves 
a series of ordered, complicated cellular mechanisms of injury: oxidative damage, 
excitotoxicity, inflammation and apoptosis, which are interconnected with each other. 
There is no one-step solution to these problems. Therefore, multi-targeting drugs will 
be needed to deal with ischemia. 
Danshen and Gegen were being used traditionally for cardiovascular diseases, 
with their blood stasis dispersing and hypertension relieving effects. Previous studies 
in our laboratory showed that Danshen-Gegen 7:3 (v/v) water extract protected 
cardiac cell viability in ex vivo IR, increased plasma anti-oxidant level, as well as 
possessed anti-oxidative property in in vitro free radical scavenging tests (Leung, 
2003; Wong, 2007). In these regards, DG extract might be useful for the management 
of cerebral IR. 
In the present study, middle cerebral artery occlusion (MCAO) was employed to 
mimic the condition of transient cerebral ischemia by using an intraluminal filament 
method and reperfusion was achieved by retracting the filament. From our results, 
the pretreatment of DG aqueous extract was shown to protect against transient 
141 
Chapter 7 General discussion 
cerebral ischemia by decreasing the percentage of brain infarction and improving the 
neurological deficit in MC AO-operated rats. The brain infarction and neurological 
deficit were assessed 24 hours after reperfusion. In this short period, the mechanisms 
of inducing cellular injury in brain were probably oxidative stress and excitotoxicity 
(Walz, 1999; Gusev & Skvortsova, 2003). Induction of the expression of 
anti-oxidative enzymes had been demonstrated to be a cellular mechanism for the 
protection of transient cerebral ischemia within 24 hours of reperfusion by previous 
studies (Kuang et al., 2006; Saleem et aL, 2006; Zhan & Yang, 2006). Due to the 
limitation of the study design, brain infarction could not be measured together with 
the anti-oxidative enzyme activity in brain as both measurements employed the same 
tissue sample. Hence, another set of animals on the same protocol was conducted for 
measuring the activities of anti-oxidative enzymes instead of brain infarction. Our 
results showed that high dose of DG extract increased the activities of SOD, catalase 
and GPX. As a result, the protective effect of DG extract against brain infarct would 
be, at least partly, due to the induction on the anti-oxidative enzymes SOD, catalase 
and GPX. In previous studies, it was shown that danshensu and protocatechuic 
aldehyde (after metabolized into protocatechuic acid) from Danshen, and puerarin 
from Gegen were able to cross the blood-brain barrier (Prasain et al, 2004; Zhang et 
al., 2011). As these compounds were detected in the HPLC profile of our DG extract, 
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it could be expected that these compounds would have crossed the blood-brain 
barrier and acted directly on the brain to exert the protective effects. 
Blood coagulation on damaged endothelium at the ischemic site might 
complicate ischemic conditions by causing further ischemia (Xu et al., 2010). In the 
anti-blood coagulation test, DG extract pretreatment showed anti-blood coagulation 
effects on rat tail bleeding test. The effects should be mediated by inhibiting the 
extrinsic pathway of blood coagulation, as well as inhibiting platelet aggregation. DG 
extract showed a milder effect than warfarin, but the risk of uncontrolled bleeding 
might also be smaller. As DG extract exhibits anti-blood coagulation effects, DG 
extract might also have preventive effects towards ischemia, together with its 
protective effects. 
Warfarin is commonly used in patients with atrial fibrillation (Wolf et al., 1999) 
as well as recovering stroke patients (Caplan, 2000) to prevent ischemia. In 
comparing the present results, DG and warfarin both showed anti-coagulation effects. 
Therefore, if DG extract is to be applied clinically on warfarin-treated patients, there 
might be additive effect in increasing the risk of internal bleeding. The dose of 
warfarin therefore should be monitored cautiously in order to minimize the risk of 
internal bleeding or uncontrolled bleeding, which could be life-threatening to the 
patients. The warfarin dose could be lowered and coagulation should be closely 
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monitored by tests such as prothrombin time. However, the benefit of applying DG 
extract is that besides anti-blood coagulation, it also shows anti-oxidative effects, so 
that it is a multi-targeting drug towards neuroprotection after ischemia. 
Besides the protective effect on cell viability, another concern of recovering 
stroke patients is the cognitive function of the brain. The shuttle box behavioral test 
was employed to evaluate the retention of memory in associating a stimulus and 
response after cerebral ischemia, which could represent in part the cognitive function 
of the brain. In our study, the rats were trained before ischemia to avoid an electric 
shock after a light and sound stimulus was given, and the retention of this ability was 
evaluated after IR. However, DG extract pretreatment or pre + post treatment failed 
to improve the performance in the shuttle box after ischemia. In this experiment, the 
shuttle box testing was carried out on 4 - 6 days after IR. In this period, in addition 
to oxidative damage and excitotoxicity, the mechanisms of inflammation and 
apoptosis would have been initiated (Walz, 1999; Gusev & Skvortsova, 2003). For 
the pretreatment group, DG extract intervention was discontinued after IR. The 
residual DG extract might be able to protect the cells from oxidative damage in the 
acute time after ischemia, but might not be able to protect against the chronic 
inflammation and apoptosis. However, for the pre + post group, improvement was 
seen on neurological score and brain infarct, which suggested continuous 
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administration would be needed for chronic period after ischemia. A larger number of 
samples might be needed to validate the result since large variation was seen in our 
study. 
In the present study, significant results were mainly achieved with the 3 g/Kg 
DG extract group, which is ten times the human equivalent dose. Hence, the safety of 
application of this dosage in human needs further investigation. However, lower 
doses should also be beneficial as dose-dependent effects were observed in the brain 
infarction and neurological score reduction, anti-oxidative enzyme induction and 
anti-blood coagulation experiments. 
In conclusion, our results showed that DG extract is a multi-targeting drug 
towards cerebral ischemia. Pretreatment of DG extract was shown to be beneficial to 
cell damage and neurological deficit in the acute phase of ischemia, probably by 
anti-oxidation and also anti-blood coagulation. However, continuous intervention 
would be needed to deal with the later cell damage pathways of inflammation and 
apoptosis. On the other hand, the effect on memory retention in active avoidance in 
the shuttle box was not observed in our study. 
7.2 Clinical significance of the study 
This was the first study on the effect of the DG extract on cerebral ischemia. DG 
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extract pretreatment was shown to improve acute ischemic cell damage. For chronic 
stage, continuous treatment of DG extract was needed. Moreover, DG extract 
possessed anti-coagulation effect. Our result suggested that it might have preventive 
effect against stroke. However, as mentioned above, the dosage required for 
significant effect was high (lOX HED). It would be worthwhile to explore the effect 
of lower doses before taking on a clinical trial, as dose-dependent effects were 
observed in most of the experiments. Therefore, the current results might suggest and 
shed light of using DG extract as health supplement in the management of stroke. 
7.3 Limitations of the study 
Normal young rats were used in our study. However, stroke occurs more often 
in the elderly, who are usually suffering from other chronic diseases such as 
hypertension or diabetes mellitus. These health problems might lead to more severe 
damage in ischemia, and reduce the effect of drug treatment. Therefore, to more 
accurately simulate stroke in elderly patients, older rats with induced disease could 
be used, such as the spontaneously hypertensive rats (SHRs) or rats induced with 
diabetes or fed with high cholesterol diets. 
In the intraluminal filament MCAO model used, reperfusion was achieved by 
retracting the filament from the vessel. This differed from the clinical situation, in 
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which reperfusion was achieved by thrombolysis. Hence, the thrombolytic effect of 
DG extract could not be evaluated using the current study model. To address the 
thrombolytic property, ischemia could be induced by insertion of blood clots 
generated ex vivo, and transported to the MCA by a catheter (Wang-Fischer, 2009). 
However, this model is complicated and the location of ischemia might be variable 
due to the differences in clot size. 
The performance in the shuttle box avoidance test was not only affected by the 
stimulus-response association memory, but also the motor ability of the rats. As the 
rats might suffer sensory or motor deficits after ischemia, these might affect the rat's 
sensation towards the stimuli as well as movement ability. Moreover, depression 
often resulted after ischemia, which rendered the rats a lower initiative of movement. 
These would lower the performance in the shuttle box. 
7.4 Future work 
From the shuttle box test results, pretreatment groups lacked protection against 
late mechanisms of cell damage, inflammation and apoptosis. The effect of DG 
extract on inflammation and apoptosis should be further investigated. Level of 
inflammatory cytokines, such as TNF-a, IL-ip and IL-6 in blood could be 
determined. It was suggested in previous studies that Danshen and salvianolic acid B 
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was able to inhibit the TNF-a induced expression of adhesion molecules including 
E-selectin, ICAM-1 and VCAM-1 (Ren et al., 2002). Puerarin from Gegen was also 
shown to have TNF-a down-regulating effect (Chang et al., 2009). For apoptosis, 
puerarin was able to down-regulate caspase 3, one of the major enzymes catalyzing 
the apoptotic pathway (Xu et aL, 2005). Therefore, it is expected that the DG extract 
would have anti-inflammatory and anti-apoptosis properties and needs to be 
confirmed in future study. 
Depression was common after ischemia (DeVries et al., 2001). It was associated 
with a decreased level of spontaneously activity (Onaivi et aL, 1990), which would 
in turn affect performance in the shuttle box experiment. The effect of the DG extract 
on depression could be investigated using the open field test (Katz et al., 1981), or 
the learned helplessness test (Cryan et al., 2002). These tests could give an idea 
whether DG extract could improve depression after ischemia. 
Moreover, the present study only evaluated the effect of DG extract on the 
cerebrum. Further studies on the effect on cerebellum could be carried out in future, 
which would give an insight on the effect of DG extract on the coordination and 
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